Nova Ltd.
(Translation of Registrant’s name into English)
|
Israel
(Jurisdiction of incorporation or organization)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Ordinary Shares
|
NVMI
|
The Nasdaq Global Select Market
|
|
|
|
Page |
1 | |||
1 | |||
1 | |||
1 | |||
|
3A. |
Selected Financial Data |
1 |
|
3B. |
Capitalization and Indebtedness |
1 |
|
3C. |
Reasons for the Offer and Use of Proceeds |
1 |
|
3D. |
Risk Factors |
1 |
|
28 | ||
|
4.A |
History and Development of the Company |
28 |
|
4.B |
Business Overview |
29 |
|
4.C |
Organizational Structure |
40 |
|
4.D |
Property, Plant and Equipment |
40 |
|
41 | ||
|
41 | ||
|
5.A |
Operating Results |
45 |
|
5.B |
Liquidity and Capital Resources |
47 |
|
5.C |
Research and Development, Patents and Licenses, etc. |
48 |
|
5.D |
Trend Information |
50 |
|
5.E |
Critical Accounting Estimates |
50 |
|
53 | ||
|
6.A |
Directors and Senior Management |
53 |
|
6.B |
Compensation |
56 |
|
6.C |
Board Practices |
58 |
|
6.D |
Employees |
65 |
|
6.E |
Share Ownership |
65 |
|
6.F |
Disclosure of Registrant’s Action to Recover Erroneously Awarded Compensation. |
66 |
|
67 | ||
|
7.A |
Major Shareholders |
67 |
|
7.B |
Related Party Transactions |
68 |
|
7.C |
Interest of Experts and Counsel |
69 |
|
69 | ||
|
8.A |
Consolidated Statements and Other Financial Information |
69 |
|
8.B |
Significant Changes |
69 |
|
69 | ||
|
9.A |
Offer and Listing Details |
69 |
|
9.B |
Plan of Distribution |
69 |
|
9.C |
Markets |
70 |
|
9.D |
Selling Shareholders |
70 |
|
9.E |
Dilution |
70 |
|
9.F |
Expenses of the Issue |
70 |
|
70 | ||
|
10.A |
Share Capital |
70 |
|
10.B |
Memorandum and Articles of Association |
70 |
|
10.C |
Material Contracts |
70 |
|
10.D |
Exchange Controls |
70 |
|
10.E |
Taxation |
71 |
|
10.F |
Dividends and Paying Agents |
85 |
|
10.G |
Statements by Experts |
85 |
|
10.H |
Documents on Display |
85 |
|
10.I |
Subsidiary Information |
85 |
|
10.J |
Annual Report to Security Holders |
85 |
|
85 | ||
|
86 | ||
|
86 | ||
86 | |||
86 | |||
86 | |||
86 | |||
87 | |||
87 | |||
87 | |||
87 | |||
88 | |||
88 | |||
88 | |||
88 | |||
|
88 | ||
|
88 | ||
|
89 | ||
|
89 | ||
90 | |||
90 | |||
90 | |||
90 | |||
|
• |
Increased cybersecurity threats and more sophisticated computer crime could disrupt our business. |
|
• |
We depend on international sales, which expose us to foreign political and economic risks. |
|
• |
We are subject to laws and regulations that could restrict our operations such as economic sanctions and export restrictions.
|
|
• |
Changes in global trade policies and other factors beyond our control may adversely impact our business, financial condition and
results of operations. |
|
• |
Changes in the U.S. taxation of international business activities or the adoption of other tax reform policies could materially impact
our business, results or operations and financial condition. |
|
• |
We may be affected by instability in the global economy and by financial turmoil. |
|
• |
Because we derive a significant portion of our revenues from sales in Asia, our sales could be hurt by instability of Asian economies.
|
|
• |
Our business is subject to risks related with doing business in China. |
|
• |
Because of the technical nature of our business, our intellectual property is extremely important to our business, and our inability
to protect our intellectual property could harm our competitive position. |
|
• |
There has been litigation involving intellectual property rights in the semiconductor and related industries, and similar litigation
could force us to divert resources to defend against such litigation or deter our customers from purchasing our systems. |
|
• |
We may incorporate open-source technology in some of our software and product, which may expose us to liability and have a material
impact on our product development and sales. |
|
• |
We may use AI technologies which may expose us to liability and have a material impact on our product development. |
|
• |
We operate in an extremely competitive market, and if we fail to compete effectively, our revenues and market share will decline.
|
|
• |
If we do not respond effectively and on a timely basis to rapid technological changes, our ability to attract and retain customers
could be diminished, which would have an adverse effect on our sales and ability to remain competitive. |
|
• |
The ongoing consolidation in our industry may harm us if our competitors are able to offer a broader range of products and greater
customer support than we can offer or if our main suppliers cease delivery of important component as a result of being acquired by a larger
company. |
|
• |
The markets we target are cyclical and it is difficult to predict the length and strength of any downturn or expansion period.
|
|
• |
Our operations may be delayed or interrupted and our business could suffer if we violate environmental, safety and health, or ESH,
regulations. |
|
• |
Challenges in designing or implementing our new ERP system could negatively impact our business and operations. |
|
• |
Pricing and demand for our specific product lines could substantially reduce our sales. |
|
• |
We depend on a small number of large customers, and the loss of one or more of them could significantly lower our revenues.
|
|
• |
Our inability to significantly reduce spending during a protracted slowdown in the semiconductor industry could reduce our prospects
of achieving continued profitability. |
|
• |
There can be no assurance that revenues from future products or product enhancements will be sufficient to recover the development
costs. |
|
• |
New product lines that we may introduce in the future may contain defects, which will require us to allocate time and financial resources
to correct. |
|
• |
If any of our systems fail to meet or exceed our internal quality specifications, we cannot ship them until such time as they have
met such specifications. |
|
• |
Our dependence on a single manufacturing facility per product line magnifies the risk of an interruption in our production capabilities.
|
|
• |
Our lease agreements for our Manufacturing Facilities include provisions that exempt the landlord and others from liability for damages
to our Manufacturing Facilities. |
|
• |
Shipment changes or cancellation may render our backlog not a reliable indicator of actual sales and financial results. |
|
• |
We may not be able to successfully complete and integrate current and/or future acquisitions. |
|
• |
We depend on continuous cooperation with Process Equipment Manufacturers (“PEMs”) to enable sales of our systems which
are integrated with the process equipment. |
|
• |
Some of our commercial agreements with PEMs and customers may include exclusivity provisions and limitations on the use of certain
intellectual property which could limit or prevent future business relationships with third parties. |
|
• |
We depend on a limited number of suppliers, and in some cases a sole supplier. |
|
• |
The disclosure rules regarding the use of conflict minerals may affect our relationships with suppliers and customers. |
|
• |
Our lengthy sales cycle increases our exposure to customer delays in orders, which may result in obsolete inventory and volatile
quarterly revenues. |
|
• |
Our inability to attract, recruit, retain highly skilled key personnel. |
|
• |
Conditions in Israel, including Israel’s conflicts with Hamas and other parties in the region, as well as political and economic
instability, may adversely affect our business, our results of operations and our ability to raise additional funds. |
|
• |
Our convertible senior notes may impact our financial results, dilute existing shareholders, and create downward pressure on the
price of our ordinary shares. |
|
• |
Currency fluctuations could harm our profit margins. |
|
• |
We received certain research and development grants, which could impose restrictions on our ability to use technology developed under
these programs. |
|
• |
Certain shareholders may control the outcome of matters submitted to a vote of our shareholders, including the election of directors.
|
|
• |
The market price of our ordinary shares may be affected by a limited trading volume and may fluctuate significantly. |
|
• |
We may be classified as a “passive foreign investment company” for U.S. income tax purposes, which could have significant
and adverse tax consequences to U.S. shareholders. |
|
• |
The rights and responsibilities of our shareholders are governed by Israeli law and differ in some respects from the rights and responsibilities
of shareholders under U.S. law. |
|
• |
Our shares are listed for trade on more than one stock exchange. |
|
• |
instability in political or economic conditions, including but not limited to inflation, recession, foreign currency exchange restrictions
and devaluations, restrictive governmental controls on the movement and repatriation of earnings and capital, and actual or anticipated
military or political conflicts, , particularly in emerging markets, including but not limited to, the impeachment motion against the
South Korean President Yoon Suk-Yeol; rising inflation and elevated U.S. budget deficits and overall debt levels, including as a result
of federal pandemic relief and stimulus legislation and/or economic or market and supply chain conditions, can put upward pressure on
interest rates and could be among the factors that could lead to higher interest rates in the future. Higher interest rates could adversely
affect our overall business or reduce our liquidity. |
|
• |
intergovernmental conflicts or actions, including but not limited to armed conflict, trade wars and acts of terrorism or war, including
the current war between Russia and the Ukraine, the war between Hamas and Israel and the limited military operations in Lebanon, Syria,
Yemen and other areas in the Middle East, as well as the tensions between Taiwan and China and the Chinese actions in the South China
Sea; and |
|
• |
interruptions to the Company’s business with its largest customers, distributors and suppliers resulting from but not limited
to, strikes, shortage in raw materials and subcomponents due to geopolitical situation and financial instabilities. For instance, trade
restrictions, changes in tariffs and import and export license requirements could adversely affect our ability to sell our products in
the countries adopting or changing those restrictions, tariffs or requirements. This could reduce our sales by a material amount.
|
|
• |
trade protection measures, such as tariff increases, and import and export licensing and control requirements; |
|
• |
potentially negative consequences from changes in tax laws; |
|
• |
difficulties associated with the Chinese legal system, including increased costs and uncertainties associated with enforcing contractual
obligations in China; |
|
• |
historically, lower protection of intellectual property rights; |
|
• |
changes and volatility in currency exchange rates; |
|
• |
unexpected or unfavorable changes in regulatory requirements; and |
|
• |
local preference of emerging local competitors in China. |
|
• |
pending patent applications will be approved; or |
|
• |
any patents will be broad enough to protect our technology, will provide us with competitive advantages or will not be challenged
or invalidated by third parties. We also cannot assure that others will not independently develop similar products, duplicate our products
or, if patents are issued to us, design around these patents. Furthermore, because patents may afford less protection under foreign law
than is available under U.S. law, we cannot assure that any foreign patents issued to us will adequately protect our proprietary rights.
|
|
• |
result in our loss of proprietary rights; |
|
• |
subject us to significant liabilities, including triple damages in some instances; |
|
• |
require us to seek licenses from third parties, which licenses may not be available on reasonable terms or at all; or |
|
• |
prevent us from selling our products. |
|
• |
the contribution and value our solutions bring to our customers; |
|
• |
our product innovation, quality and performance; |
|
• |
our global technical service and support; |
|
• |
the return on investment (ROI) of our equipment and its cost of ownership; |
|
• |
the breadth of our product line; |
|
• |
our success in developing and marketing new products; and |
|
• |
the extendibility of our products. |
|
• |
our continuing need to invest in research and development; |
|
• |
our continuing need to market our new products; and |
|
• |
our extensive ongoing customer service and support requirements worldwide. |
|
• |
diverting management’s attention and other resources from our ongoing business concerns; |
|
• |
entering markets in which we have no direct prior experience; |
|
• |
improperly evaluating new services, products and markets; |
|
• |
being unable to maintain uniform standards, controls, procedures and policies; |
|
• |
failing to comply with governmental requirements pertaining to acquisitions of local companies or assets by foreign entities;
|
|
• |
being unable to integrate new technologies or personnel; |
|
• |
incurring the expenses of any undisclosed or potential liabilities; and |
|
• |
the departure of key management and employees. |
Technology |
Product Line |
Key applications |
Product families |
• Broadband Spectrophotometry
• Scatterometry
• Spectral Reflectometry
• Imaging and Image Processing
|
Dimensional Optical CD Integrated Metrology |
Critical Dimensions
Thin films
Wafer topography
|
Nova i Platform
Nova Astera |
Dimensional Optical CD Stand-Alone Metrology |
Nova T-platform
Nova MMSR
Nova Velo CD
| ||
• Spectral Interferometry |
Nova Prism | ||
• X-Ray Photoelectron Spectroscopy
• X-Ray Fluorescence
|
X-Ray
Materials
Metrology |
Thin film
Composition
|
Nova VeraFlex |
• Secondary Ion Mass Spectrometry
|
SIMS Materials
Metrology |
Composition depth-profiling
|
Nova Metrion |
• Raman Spectroscopy |
Optical Materials Metrology |
Strain
Crystallinity
Composition
|
Nova Elipson |
• Computational Modeling for Metrology
Platforms |
Physical modeling (Modeling Software Solutions) |
|
Nova MARS |
• Machine Learning
• Advanced Algorithms
|
Mathematical modeling algorithms (Software solutions) |
|
Nova FIT for Films CD Metrology
Nova FIT for Material Metrology |
• Big Data Analytics
• High Power Computing
|
Fleet Management (Software solutions) |
|
Nova FM
Nova HPC
QED |
• Titration – various
types
• CVS, CPVS, PCGA
• Spectrophotometry
• HPLC
• Dynamic Surface Tension
• pH, conductivity, density
|
Chemical Process Control – Analysis and Replenishment |
Electroplating process applications in interconnect, advanced packaging, and PCB markets |
Nova Ancolyzer
Nova AncoScene
Nova AncoFlex |
• Solid dosing
|
Metal Replenishment
|
Powder dosing specialty metal oxide materials for electroplating applications |
Nova DMR |
|
• |
Nova MARS - Nova MARS software package is a multi-channel metrology modeling engine designed for the most advanced 3D structures
in advanced process nodes of semiconductor manufacturing. It is a complete modeling solution for scatterometry and spectral interferometry
models’ development, material characterization and recipe optimization which is crucial for facing increasing challenges in semiconductor
metrology. The Nova MARS also injects physical and process related knowledge to solve complex structures. |
|
• |
Nova FIT - The Nova FIT modeling suite complements traditional modeling of Optical Critical Dimensions and Materials by machine learning
and data-driven algorithmic solutions. The algorithmic suite works independently or in conjunction with Nova MARS physical modeling engine
and Nova’s Fleet Management solution, to improve metrology performance, optimize throughput, speed up time to solution, and expand
the metrology envelope for enriched process control. For optical CD, Nova FIT embeds advanced machine learning and big data architecture
into optical modeling. In every permutation of the solution, Nova Fit enhances the way customers utilize metrology measurement data to
tighten process windows, avoid process excursions, and improve yield. |
|
• |
Nova’s Centralized Fleet Management and Control - Nova’s Fleet Management and Performance Monitoring Center simplify
the management and enhance the productivity of Nova tools in the fabrication site. The platform’s ability to process and analyze
large amounts of fleet and metrology data using advanced data analytic tools provides our customers with intelligent and predictive insights
on tool performance and process trends. |
|
• |
Nova HPC - The Nova HPC is a High-Performance Computing solution, which is designed to accelerate Nova MARS and Nova FIT work processes.
Nova HPC significantly expedites application development by accelerating library-building, real time regression and recipe-setting processes.
Its advanced computing hardware design enables optimization of Nova’s proprietary algorithm performance, thus enabling the most
calculation-demanding application development. |
|
• |
VeraFlex- Nova’s VeraFlex combines enhanced XPS (X-Ray photoelectron
spectroscopy) capability with an optional unique low energy XRF (X-Ray fluorescence) channel to address logic and memory device fabrication
challenges. This innovative inline technology is a surface-sensitive quantitative spectroscopic technique that is used to determine the
elemental composition and thickness of thin films. When incorporating the Nova Fit advanced suite of machine learning applications, the
platform offers enhanced throughput and precision performance of established applications and maximizes system productivity.
|
|
• |
Nova Metrion -
Nova Metrion - targets process control of 3D logic and
memory semiconductor devices. The technology enables advanced materials profile measurements by bringing secondary ion mass spectrometry
(SIMS) into semiconductor production lines on both monitor and product wafer. The Nova Metrion provides quantitative and actionable results
on depth profiling of compositional information with high-depth resolution and precision. |
|
• |
Nova Elipson - Nova Elipson utilizes Raman spectroscopy, a vibrational spectroscopy technique, to detect multiple material properties
such as strain, crystallinity, phases, grain size and composition. The combination of a small spot and high speed of this non-destructive,
optical method makes it a metrology of choice for both memory and logic applications. |
|
• |
Nova FIT for Materials Metrology – a server based solution, when used in conjunction with our VeraFlex IV product, enables
higher measurement throughput and higher precision for certain use cases. |
|
• |
Nova AncoScene– the Nova AncoScene is an industry-standard chemical metrology solution for damascene copper and cobalt plating
interconnects applications, qualified by leading global manufacturers for operation in advanced nodes production processes. The solution
supports a continuously growing range of copper and cobalt baths and applications and offers a fully automated analysis of bath components,
overall plating performance, excursions, trends alarms and warnings, and overall process control. |
|
• |
Nova Ancolyzer – the Ancolyzer is a fully automated online chemical metrology platform designed with the most flexible architecture
for advanced packaging processes. Nova’s Ancolyzer offers superior analytical performance and supports a wide variety of analytical
techniques for process control. The platform’s flexible and scalable architecture is configured to the specific process analysis
and replenishment requirements. The platform’s superior accuracy and precision are coupled with uncompromising reliability and the
highest availability. |
|
• |
Nova DMR – the Nova DMR offers economical replenishment of metals in a plating bath. This significantly extends the bath chemicals’
lifetime and improves the plater utilization. DMR provides fully automatic powder container docking for uninterrupted operation and eliminates
the constant increase in bath volume, reducing the need for bleed and feed or full bath dump. Thus, reducing environmental impact and
minimizing operational risks and costs. The platform integrates with Nova Ancolyzer and can directly connect to any process tools.
|
|
• |
Nova AncoFlex - Nova AncoFlex™ is an industry-standard fully automated inline chemical metrology solution for copper PCB and
IC-substrate production processes. The solution supports a continuously growing range of copper baths and applications and provides excellent
lifetime monitoring of bath composition and performance. The platform combines reported and controlled accuracy and precision with uncompromising
reliability and the highest availability. |
|
2022 |
2023 |
2024 |
|||||||||
Total revenues from five largest customers |
57 |
% |
52 |
% |
53 |
% | ||||||
Range of revenues from five largest customers |
6-23 |
% |
5-19 |
% |
6-18 |
% |
Name of Subsidiary |
Place of Incorporation |
Nova Measuring Instruments, Inc. |
Delaware, U.S. |
Nova Measuring Instruments K.K. |
Japan |
Nova Measuring Instruments Taiwan Ltd. |
Taiwan |
Nova Measuring Instruments Korea Ltd. |
Korea |
Nova Measuring Instruments GmbH |
Germany |
Nova Measuring Instruments (Shanghai) Co., Ltd. |
China |
Nova Measuring Instruments Singapore Pte Ltd |
Singapore |
Location |
Purpose of use |
Approximate
SQM |
Expiration date |
Israel
Rehovot and Ness Ziona
|
Offices, manufacturing and laboratories
|
16,000
|
August 2029 with an option to extend the lease period by two periods of five years
each, subject to customary conditions. Ness Ziona 2800 sqm lease is expected to end in January 2026 |
US
Fremont California
|
Offices, manufacturing and laboratories |
9,300 |
August 2034 with an option to extend for an additional five years, subject to customary conditions.
|
Germany
Bad Urach |
Offices, manufacturing and laboratories |
6,500 |
The facility is owned by the Company and as of January 2025, has fully replaced the Pliezhausen facility.
|
Germany
Pliezhausen
|
Offices, manufacturing and laboratories |
3,500 |
March 2025, to be replaced by the Bad Urach facility.
|
Taiwan
Hsinchu |
Offices and laboratories |
2,000 |
Ranging between 2025 and 2031 |
US, China, Korea, Taiwan, Japan, Singapore |
Offices and laboratories |
Less than 2,000 each |
Ranging between 2024 and 2029. |
|
• |
Record product and service sales results. |
|
• |
Record profitability and earnings per share |
|
• |
Diversified customers mix, across multiple territories. |
|
• |
Further expansion into advanced packaging with new and existing products. |
|
• |
Further market adoption of Nova’s advanced portfolio: |
|
o |
Materials, chemical and dimensional metrology solutions. |
|
o |
Hardware and software coupling. |
|
o |
Machine learning and AI capabilities to complement physical modeling. |
|
o |
Holistic offering, including Integrated and Standalone metrology. |
|
• |
Continued proliferation of Nova’s newly announced solutions of Elipson, Metrion and AncoScene products. |
|
• |
Record sales of our Optical CD stand-alone solutions, and continued evolution with new generations of Integrated and Standalone metrology
platforms. |
|
• |
Record sales of materials and chemical metrology solutions. |
|
• |
Continued investments in research and development programs aimed to generate new organic growth engines for process control.
|
|
• |
Deepening collaboration with research institutes and customers' development centers, utilizing a variety of our products, leading
to our positioning as a long-term technology development and high-volume manufacturing partner. |
|
• |
ESG (Environment, Social and Governance) – In 2024 we worked to update our first ESG review. We are determined as a company
to play a vital role in creating a world that values equality, safety and environmental health for the benefit of future generations to
come. We remain committed to proactively invest in embedding social responsibility and sustainability as part of our culture and business
management to support our values. |
|
• |
The acquisition of Sentronics,
a privately held company headquartered in Germany, closed on January 30, 2025. Sentronics is a global provider of wafer metrology tools
for backend semiconductor fabrication. Sentronics develops flexible and modular metrology tools equipped with multiple metrology sensors
for a variety of critical dimension applications, including thickness, roughness, and topography. The addition of Sentronics’ modular
dimensional metrology technology to Nova’s dimensional metrology portfolio enables Nova to diversify its offering in the growing
field of advanced wafer level packaging and specialty devices. |
|
• |
Investing in organization development to enhance our human capital and the strength of our global teams based on our values and culture.
|
|
• |
Continue to strengthen our competitive market position, through unique innovation and technical leadership. |
|
• |
Continue executing our innovation and development plans to meet future industry challenges. |
|
• |
Continue executing our well-defined strategy to reach $1B USD by 2027 in revenues, organically and inorganically. The strategy defines
the Company’s growth path in revenue, customers, technology and financial performance. |
|
• |
Expand our total available markets by addressing new emerging metrology applications and markets sectors, through solutions delivery
to the challenging buildup of advanced Logic technology nodes, memory scaled 3D-NAND nodes and DRAM scaled devices at leading edge customers.
|
|
• |
Continue delivering metrology systems for the trailing edge technology nodes and to advanced packaging customers to support new applications
ramp up and expansions. |
|
• |
Continue the collaborations and joint research programs with leading semiconductor manufacturers and relevant leading research institutes.
|
|
• |
Continue innovation and diversification of our products through several new product introductions to extend the Company’s market
leadership and total available market. |
|
• |
Continue our plans to generate revenues and competitive edge through SW algorithms and Machine Learning solutions. |
|
• |
Strengthening the partnership with our customers and build a “Customer Centric” approach to accommodate and deliver customers’
requirements along the semiconductor lifecycle. |
|
• |
Continue investing in developing new approaches and methods for inline materials process control. |
|
• |
Continue investing in our chemical metrology product development and enhance our product offering. |
|
• |
Create synergy between our product lines towards a combined offering for advanced applications, which require dimensional, material
and chemical metrology. |
|
• |
Grow our production facilities and offices footprint to meet semiconductor demand and our strategic plans and continue to develop
modern and streamlined core business processes through new ERP and Service CRM infrastructure. |
|
• |
Elevate our investment in ESG programs in order to promote social responsibility programs through our five pillars program (for details,
refer to the Environmental, Social and Governance (ESG) chapter in Item 4.B in this Annual Report). |
|
• |
Build an extensive roadmap for Sentronics products in order to broaden their portfolio and cater to additional applications.
|
|
• |
Create synergy between Nova and Sentronics’ technologies towards a combined and enhanced offering for advanced packaging applications.
|
|
• |
Leverage Nova’s extensive market presence and exposure to drive Sentronics sales to new heights. |
|
• |
Continue looking for investment opportunities to broaden our portfolio and enrich our brand. |
|
• |
Meeting strategic, development, operational and delivery targets considering the macro economical, geopolitical and trade restriction
issues across the globe and the current conditions in Israel. |
|
• |
On time delivery of the required solutions to meet the current and future needs of our existing and new customers. |
|
• |
Correctly understanding the market trends and competitive landscape to ensure our products retain proper differentiation to win customer
confidence. |
|
• |
Creating aggressive, innovative and competitive roadmap deliverables at reasonable costs to properly control expenses. |
|
• |
Identifying the metrology evolution roadmap for future industry needs to meet process control requirements and lead the market.
|
|
• |
Achieving long-term growth targets while supporting extensive growth in all our activities. |
|
• |
Building a solid global infrastructure and production capacity to accommodate further growth. |
|
• |
Failure to design, implement and smoothly transition to the new ERP system. |
|
• |
Optical metrology has become an enabler for the industry over the last few years. |
|
• |
Materials metrology has been widely adopted by leading memory and logic/foundry customers. We expect further adoption in the next
few years. |
|
• |
The growing adoption of our metrology portfolio in the advanced packaging market. |
|
• |
The growing need for chemical process control and replenishment solutions, driven by ESG and environment sustainability trends for
reduction in chemical materials waste. |
|
• |
Our unique metrology portfolio, combining optical, X-Ray and chemical metrology for both dimensions and materials. This provides
the most advanced portfolio, combining the best innovative metrology capabilities with the best reliability and return on investment.
|
|
• |
The ability to provide a unique and differentiated technology portfolio sets us apart from the competition and adding a competitive
edge to our offering. |
|
• |
Our solutions are well accepted by leading customers that allow us to gain more market share with additional process steps and new
applications. |
|
• |
Our ability to closely team with our customers allows us to predict the industry evolution and process control challenges and by
that introduce innovative metrology roadmap to solve industry needs. |
|
• |
Our diversified portfolio, which is a result of continuous investment in research and development, is becoming more attractive to
our customers. |
|
• |
Extending our solutions’ base to include hardware and software elements in a coupled offering. |
|
• |
Successful track record in completing and integrating inorganic products, as a result of M&A, which allows us to diversify our
product offering to expand our addressable markets. |
|
• |
Well controlled and efficient operating model to support our profitable growth and operational resiliency. |
|
2022 |
2023 |
2024 |
|||||||||
|
||||||||||||
Revenues from product sales |
81 |
% |
78 |
% |
80 |
% | ||||||
Revenues from services |
19 |
% |
22 |
% |
20 |
% | ||||||
Total revenues |
100 |
% |
100 |
% |
100 |
% | ||||||
|
||||||||||||
Cost of products sale |
34 |
% |
32 |
% |
31 |
% | ||||||
Cost of services |
11 |
% |
12 |
% |
11 |
% | ||||||
Total cost of revenues |
45 |
% |
43 |
% |
42 |
% | ||||||
|
||||||||||||
Gross profit |
56 |
% |
57 |
% |
58 |
% | ||||||
|
||||||||||||
Operating expenses: |
||||||||||||
Research and development expenses, net |
16 |
% |
17 |
% |
16 |
% | ||||||
Sales and marketing expenses |
9 |
% |
10 |
% |
10 |
% | ||||||
General and administrative expenses |
4 |
% |
4 |
% |
4 |
% | ||||||
Total operating expenses |
29 |
% |
31 |
% |
30 |
% | ||||||
|
||||||||||||
Operating profit |
26 |
% |
26 |
% |
28 |
% | ||||||
|
||||||||||||
Financial income (expense), net |
2 |
% |
4 |
% |
4 |
% | ||||||
Income before income taxes |
28 |
% |
30 |
% |
32 |
% | ||||||
Income tax expenses |
3 |
% |
4 |
% |
5 |
% | ||||||
|
||||||||||||
Net income |
25 |
% |
26 |
% |
27 |
% |
|
2022 |
2023 |
2024 |
|||||||||||||||||||||
|
Domestic |
Abroad |
Domestic |
Abroad |
Domestic |
Abroad |
||||||||||||||||||
Electronic equipment |
3,664 |
4,155 |
2,086 |
2,867 |
1,313 |
3,077 |
||||||||||||||||||
Office furniture and equipment |
66 |
1,055 |
360 |
499 |
29 |
202 |
||||||||||||||||||
Leasehold improvements |
8,934 |
436 |
2,994 |
2,457 |
91 |
843 |
||||||||||||||||||
Land and buildings |
- |
3,004 |
- |
5,925 |
- |
11,660 |
||||||||||||||||||
Total |
12,664 |
8,650 |
5,440 |
11,748 |
1,433 |
15,782 |
|
• |
Local Manufacturing Obligation.
The terms of the grants under the Innovation Law require that we manufacture the products developed with these grants in Israel. Under
the regulations promulgated under the Innovation Law, the products may be manufactured outside Israel by us or by another entity only
if prior approval is received from the IIA (such approval is not required for the transfer of less than 10% of the manufacturing capacity
in the aggregate, as declared to be manufactured out of Israel in the applications for funding, in which case a notice should be provided
to the IIA). This approval may be given only if we abide by all the provisions of the Innovation Law and related regulations. Ordinarily,
as a condition to obtaining approval to manufacture outside Israel, we would be required to pay royalties at an increased rate (usually
1% in addition to the standard rate and increased royalties cap between 120% and 300% of the grants, depending on the manufacturing volume
that is performed outside Israel). |
|
• |
Know-How transfer limitation.
The Innovation Law restricts the ability to transfer know-how funded by the IIA outside of Israel, including by way of a license to a
non-Israeli entity. Transfer of IIA funded know-how outside of Israel requires prior approval of the IIA. The IIA approval to transfer
know-how created, in whole or in part, in connection with an IIA-funded project to third party outside Israel is subject to payment of
a redemption fee to the IIA calculated according to a formula provided under the Innovation Law that is based, in general, on the ratio
between the aggregate IIA grants to the company’s aggregate investments in the project that was funded by these IIA grants, multiplied
by the transaction consideration, taking into account depreciation mechanism, and less royalties already paid to the IIA. The regulations
promulgated under the Innovation Law establish a maximum payment of the redemption fee paid to the IIA under the above mentioned formulas
and differentiates between two situations: (i) in the event that the company sells its IIA funded know-how, in whole or in part, or is
sold as part of an M&A transaction, and subsequently ceases to conduct business in Israel, the maximum redemption fee under the above
mentioned formulas will be no more than six times the total grants received (plus accrued interest) for development of the know-how being
transferred, or the entire amount received from the IIA, as applicable; (ii) in the event that following the transactions described above
(i.e., asset sale of IIA funded know-how or transfer as part of an M&A transaction) the company undertakes to continue its R&D
activity in Israel (for at least three years following such transfer and maintain at least 75% of its R&D staff employees it had for
the six months before the know-how was transferred, while keeping the same scope of employment for such R&D staff), then the company
is eligible for a reduced cap of the redemption fee of no more than three times the amounts received (plus accrued interest) for the applicable
know-how being transferred, or the entire amount received from the IIA, as applicable. No assurance can be given that approval of any
such transfer, if requested, will be granted and what will be the amount of the redemption fee payable. |
|
• |
Licensing arrangements.
Under the terms of the Innovation Law, licensing know how developed under the IIA programs outside of Israel, requires prior consent of
IIA and payment of license fees to IIA, calculated in accordance with the licensing rules promulgated under the Innovation Law. The payment
of the license fees does not discharge the company from the obligation to pay royalties or other payments due to IIA in accordance with
Innovation Law. |
Name |
Age |
Position |
Eitan Oppenhaim (4) |
59 |
Executive Chairman of the Board of Directors |
Avi Cohen (1)(2) (4) |
71 |
Director |
Raanan Cohen (2)(3) |
69 |
Director |
Zehava Simon (1)(2)(3)(4) |
66 |
Director |
Sarit Sagiv (1)(2) |
56 |
Director |
Yaniv Garty (3)(4) |
57 |
Director |
Gabriel Waisman |
54 |
President & CEO |
Guy Kizner* |
41 |
Chief Financial Officer |
Shay Wolfling |
53 |
Chief Technology Officer |
Adrian S. Wilson |
53 |
President of US subsidiary & General Manager Material Metrology Division
|
Effi Aboody |
54 |
Corporate VP and General Manager Dimensional Metrology Division |
As of December 31, |
2022 |
2023 |
2024 |
|||||||||
Total Personnel |
1,177 |
1,202 |
1,383 |
|||||||||
Located in Israel |
505 |
516 |
586 |
|||||||||
Located abroad |
672 |
686 |
797 |
|||||||||
In operations |
280 |
287 |
293 |
|||||||||
In research and development |
462 |
477 |
585 |
|||||||||
In global business |
311 |
318 |
375 |
|||||||||
In general and administration |
124 |
120 |
130 |
Name |
Number of Ordinary
Shares Beneficially
Owned |
Percentage of Ordinary
Shares
Beneficially Owned |
||||||
FMR LLC (1)
|
2,655,264 |
9.07 |
% | |||||
Wasatch Advisors Inc. (2)
|
2,411,677 |
8.24 |
% | |||||
Menora Mivtachim Holdings
Ltd. (3) |
2,121,579 |
7.25 |
% | |||||
Migdal Insurance & Financial Holdings Ltd.
(4) |
2,286,687 |
7.81 |
% | |||||
Harel Insurance Investments & Financial Services Ltd.
(5) |
1,799,718 |
6.15 |
% |
|
(1) |
The information is based upon Schedule 13F filed with the SEC by FMR LLC, and subsidiaries
on February 13, 2025 regarding holdings as of December 31, 2024. |
|
(2) |
The information is based upon Amendment
no. 6 Schedule 13G/A filed with the SEC by Wasatch Advisors Inc. on February 12, 2025 regarding holdings as of December 31, 2024.
|
|
(3) |
The information is based upon the shareholder
notification provided to the Company by Menora Mivtachim Holdings Ltd., Menora Mivtachim Pensions and Gemel Ltd., Menora Mivtahim Insurance
Ltd., Menora Mivtachim Vehistadrut Hamehandesim Nihul Kupot Gemel Ltd. and Shomera Insurance Company Ltd. on February 17, 2025 regarding
holdings as of December 31, 2024. |
|
(4) |
The information is based upon Schedule 13G
filed with the SEC by Migdal Insurance & Financial Holdings Ltd., Migdal Insurance Company Ltd., Migdal Sal Domestic Equities, Migdal
Mutual Funds Ltd., on February 13, 2025 regarding holdings as of December 31, 2024. |
|
(5) |
The information is based upon the shareholder
notification provided to the Company by Harel Insurance Investments & Financial Services Ltd. on February 2, 2025 regarding holdings
as of December 31, 2024. |
Tax Year |
Development Region “A” |
Other Areas within Israel |
2011-2012 |
10% |
15% |
2013 |
7% |
12.5% |
2014-2016 |
9% |
16% |
2017 onwards* |
7.5% |
16% |
|
• |
An individual citizen or resident of the U.S. (as determined under U.S. federal income tax rules); |
|
• |
a corporation (or another entity taxable as a corporation for U.S. federal income tax purposes) created or organized in or under
the laws of the U.S., any state thereof, or the District of Columbia; |
|
• |
an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or |
|
• |
a trust, if (a) a U.S. court is able to exercise primary supervision over its administration and one or more U.S. persons have the
authority to control all of its substantial decisions; or (b) the trust has in effect a valid election in effect under applicable Treasury
Regulations (as defined below) to be treated as a United States person. |
|
• |
persons who own, directly, indirectly or constructively, 10% or more (by voting power or value) of our outstanding voting shares;
|
|
• |
persons who hold the ordinary shares as part of a hedging, straddle or conversion transaction; |
|
• |
persons whose functional currency is not the U.S. dollar; |
|
• |
persons who acquire their ordinary shares in a compensatory transaction; |
|
• |
broker-dealers; |
|
• |
insurance companies; |
|
• |
regulated investment companies; |
|
• |
real estate investment companies; |
|
• |
qualified retirement plans, individual retirement accounts and other tax-deferred accounts; |
|
• |
traders who elect to mark-to-market their securities; |
|
• |
tax-exempt organizations; |
|
• |
banks or other financial institutions; |
|
• |
persons subject to special tax accounting rules as a result of any item of gross income with respect to ordinary shares being taken
into account in an applicable financial statement; |
|
• |
U.S. expatriates and certain former citizens and long-term residents of the United States; and |
|
• |
Persons subject to any alternative minimum tax. |
|
• |
fails to furnish its taxpayer identification number, or TIN, which, for an individual, is ordinarily his or her social security number;
|
|
• |
furnishes an incorrect TIN; |
|
• |
is notified by the IRS that it is subject to backup withholding because it has previously failed to properly report payments of interest
or dividends; or |
|
• |
fails to certify, under penalties of perjury, that it has furnished a correct TIN and that the IRS has not notified the U.S. holder
that it is subject to backup withholding. |
|
• |
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and asset dispositions;
|
|
• |
provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our financial statements in
accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with
authorizations of our management and directors; and |
|
• |
provide reasonable assurance regarding the prevention or timely detection
of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements. Due to its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate. |
|
2023 |
2024 |
||||||
Audit Fees |
740,000 |
776,000 |
||||||
Tax Fees |
26,000 |
23,000 |
||||||
Other Fees |
25,000 |
172,000 |
||||||
Total |
791,000 |
971,000 |
Period |
(a) Total Number
of Ordinary Shares Purchased |
(b) Average Price Paid per Ordinary Share |
(c) Total Number of Ordinary Shares Purchased as Part of Publicly Announced Plans or Programs |
(d) Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in millions) |
||||||||||||
November 2024 |
58,286 |
185.10 |
311,269 |
67.68 |
||||||||||||
December 2024 |
102,232 |
187.94 |
413,501 |
48.47 |
• |
risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT environment;
|
• |
a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;
|
|
• |
the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls; and
|
• |
a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents.
|
Page
|
|
Reports of Independent Registered Public Accounting Firm (PCAOB ID No. 1281)
|
F-3 - F-6
|
F-7
|
|
F-8
|
|
F-9
|
|
F-10
|
|
F-11
|
|
F-12 - F-41
|
![]() |
Kost Forer Gabbay & Kasierer
144 Menachem Begin Road, Building A,
Tel-Aviv 6492102, Israel
|
Tel: +972-3-6232525
Fax: +972-3-5622555
ey.com
|
Valuation of excess and obsolete inventory reserve
|
|
Description of the Matter
|
The Company’s inventories totaled $156.6 million as of December 31, 2024. As described in Note 2i to the consolidated financial statements, the Company assesses the value of inventories, including raw materials, service inventory, work-in-process and finished goods, in each reporting period, and values its inventories at the lower of cost or net realizable value. Reserves for potential excess and obsolete inventory are made based on management's analysis of inventory levels, future sales forecasts, market conditions and the expected consumption.
Auditing management's estimates for valuation of inventories involved subjective auditor judgment due to the significant assumptions made by management about the future salability of the inventories. These assumptions include the assessment, by inventory category (raw materials, service inventory, work-in-process and finished goods), of future usage and market demand for the Company's products.
|
How We Addressed the Matter in Our Audit
|
We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls over the Company's excess and obsolete inventory reserve process, including management's assessment of the underlying assumptions and data.
Our substantive audit procedures included evaluating the significant assumptions stated above and the accuracy and completeness of the underlying data management used to value excess and obsolete inventory. We compared the cost of on-hand inventories to management's sales forecast. We also assessed the historical accuracy of management's estimates and performed sensitivity analyses over the significant assumptions to evaluate the changes in the obsolete and excess inventory estimates that would result from changes in the underlying assumptions.
|
![]() |
Kost Forer Gabbay & Kasierer
144 Menachem Begin Road, Building A,
Tel-Aviv 6492102, Israel
|
Tel: +972-3-6232525
Fax: +972-3-5622555
ey.com
|
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash and cash equivalents
|
157,779
|
107,574
|
||||||
Short-term interest-bearing bank deposits
|
211,877
|
119,850
|
||||||
Marketable securities (Note 3)
|
216,910
|
216,258
|
||||||
Trade accounts receivable, net of allowance of $576 and $277 at December 31, 2024 and 2023, respectively
|
139,318
|
111,256
|
||||||
Inventories (Note 4)
|
156,599
|
138,198
|
||||||
Other current assets (Note 5)
|
19,466
|
17,084
|
||||||
Total current assets
|
901,949
|
710,220
|
||||||
Non-current assets
|
||||||||
Marketable securities (Note 3)
|
225,818
|
191,351
|
||||||
Interest-bearing bank deposits and restricted cash
|
7,847
|
6,254
|
||||||
Deferred tax assets (Note 14)
|
31,639
|
23,583
|
||||||
Severance pay funds (Note 9)
|
1,043
|
1,146
|
||||||
Operating lease right-of-use assets (Note 11)
|
51,193
|
41,856
|
||||||
Property, plant and equipment, net (Note 6)
|
81,746
|
66,874
|
||||||
Intangible assets, net (Note 7)
|
31,458
|
39,184
|
||||||
Goodwill
|
48,317
|
50,080
|
||||||
Other long-term assets
|
9,412
|
3,259
|
||||||
Total non-current assets
|
488,473
|
423,587
|
||||||
TOTAL ASSETS
|
1,390,422
|
1,133,807
|
||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
||||||||
Current liabilities
|
||||||||
Convertible senior notes, net (Note 10)
|
180,564
|
197,678
|
||||||
Trade accounts payable
|
59,578
|
35,158
|
||||||
Deferred revenues
|
72,886
|
41,978
|
||||||
Operating lease current liabilities (Note 11)
|
7,169
|
6,703
|
||||||
Other current liabilities (Note 8)
|
68,033
|
41,294
|
||||||
Total current liabilities
|
388,230
|
322,811
|
||||||
Non-Current liabilities
|
||||||||
Accrued severance pay (Note 9)
|
3,302
|
3,363
|
||||||
Operating lease long-term liabilities (Note 11)
|
48,363
|
39,762
|
||||||
Deferred tax liability (Note 14)
|
8,495
|
10,574
|
||||||
Other long-term liabilities
|
14,237
|
6,545
|
||||||
Total non-current liabilities
|
74,397
|
60,244
|
||||||
Commitments and contingencies (Note 12)
|
||||||||
TOTAL LIABILITIES
|
462,627
|
383,055
|
||||||
SHAREHOLDERS’ EQUITY (Note 13)
|
||||||||
Ordinary shares, no par value - Authorized 60,000,000 shares at December 31, 2024 and 2023; Issued and Outstanding 29,278,401 and 29,013,834 at December 31, 2024 and 2023, respectively.
|
||||||||
Additional paid-in capital
|
134,951
|
139,694
|
||||||
Accumulated other comprehensive loss
|
(5,301
|
)
|
(3,325
|
)
|
||||
Retained earnings
|
798,145
|
614,383
|
||||||
Total shareholders’ equity
|
927,795
|
750,752
|
||||||
Total liabilities and shareholders’ equity
|
1,390,422
|
1,133,807
|
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Revenues:
|
||||||||||||
Products
|
538,350
|
405,037
|
464,152
|
|||||||||
Services
|
134,046
|
112,885
|
106,577
|
|||||||||
Total revenues
|
672,396
|
517,922
|
570,729
|
|||||||||
Cost of revenues:
|
||||||||||||
Products
|
210,639
|
163,981
|
191,402
|
|||||||||
Services
|
74,671
|
60,764
|
62,357
|
|||||||||
Total cost of revenues
|
285,310
|
224,745
|
253,759
|
|||||||||
Gross profit
|
387,086
|
293,177
|
316,970
|
|||||||||
Operating expenses:
|
||||||||||||
Research and development, net (Note 2S)
|
110,257
|
88,043
|
90,458
|
|||||||||
Sales and marketing
|
65,090
|
52,467
|
52,729
|
|||||||||
General and administrative
|
24,199
|
20,404
|
23,852
|
|||||||||
Total operating expenses
|
199,546
|
160,914
|
167,039
|
|||||||||
Operating income
|
187,540
|
132,263
|
149,931
|
|||||||||
Financial income, net (Note 17)
|
28,747
|
22,436
|
8,478
|
|||||||||
Income before taxes on income
|
216,287
|
154,699
|
158,409
|
|||||||||
Income tax expenses (Note 14)
|
32,525
|
18,389
|
18,196
|
|||||||||
Net income
|
183,762
|
136,310
|
140,213
|
|||||||||
Earnings per share:
|
||||||||||||
Basic
|
6.31
|
4.73
|
4.89
|
|||||||||
Diluted
|
5.75
|
4.28
|
4.43
|
|||||||||
Shares used in calculation of earnings per share (in thousands):
|
||||||||||||
Basic
|
29,113
|
28,828
|
28,697
|
|||||||||
Diluted
|
32,138
|
32,089
|
31,870
|
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Net income
|
183,762
|
136,310
|
140,213
|
|||||||||
Other comprehensive income (loss), net of tax:
|
||||||||||||
Cumulative Translation Adjustment
|
(2,951
|
)
|
2,946
|
(5,039
|
)
|
|||||||
Available-for-sale investments (Note 3):
|
||||||||||||
Unrealized gain (loss) on available-for-sale marketable securities, net
|
1,202
|
5,193
|
(6,047
|
)
|
||||||||
Cash flow hedges (Note 16):
|
||||||||||||
Unrealized loss from cash flow hedges
|
(54
|
)
|
(532
|
)
|
(2,421
|
)
|
||||||
Less: reclassification adjustment for net gain (loss) included in net income
|
(173
|
)
|
1,576
|
1,813
|
||||||||
Other comprehensive income (loss)
|
(1,976
|
)
|
9,183
|
(11,694
|
)
|
|||||||
Total comprehensive income
|
181,786
|
145,493
|
128,519
|
Accumulated
|
||||||||||||||||||||
Ordinary
|
Additional
|
Other
|
Total
|
|||||||||||||||||
Shares
|
Paid-in
|
Comprehensive
|
Retained
|
Shareholders’
|
||||||||||||||||
Number
|
Capital
|
Income (Loss)
|
Earnings
|
Equity
|
||||||||||||||||
Balance as of January 1, 2022
|
28,579,044
|
139,847
|
(814
|
)
|
334,721
|
473,754
|
||||||||||||||
ASU 2020-06 adoption (Note 10)
|
-
|
(13,770
|
)
|
-
|
3,139
|
(10,631
|
)
|
|||||||||||||
Issuance of shares upon exercise of options
|
161,416
|
90
|
-
|
-
|
90
|
|||||||||||||||
Issuance of shares upon vesting of RSU
|
191,494
|
-
|
-
|
-
|
-
|
|||||||||||||||
Share based compensation
|
-
|
16,647
|
-
|
-
|
16,647
|
|||||||||||||||
Shares repurchase at cost
|
(253,478
|
)
|
(21,416
|
)
|
-
|
-
|
(21,416
|
)
|
||||||||||||
Other comprehensive loss
|
-
|
-
|
(11,694
|
)
|
-
|
(11,694
|
)
|
|||||||||||||
Net income
|
-
|
-
|
-
|
140,213
|
140,213
|
|||||||||||||||
Balance as of December 31, 2022
|
28,678,476
|
121,398
|
(12,508
|
)
|
478,073
|
586,963
|
||||||||||||||
Issuance of shares upon exercise of options
|
133,485
|
122
|
-
|
-
|
122
|
|||||||||||||||
Issuance of shares upon vesting of RSU
|
203,128
|
-
|
-
|
-
|
-
|
|||||||||||||||
Share based compensation
|
-
|
18,286
|
-
|
-
|
18,286
|
|||||||||||||||
Shares repurchase at cost
|
(1,255
|
)
|
(112
|
)
|
-
|
-
|
(112
|
)
|
||||||||||||
Other comprehensive income
|
-
|
-
|
9,183
|
-
|
9,183
|
|||||||||||||||
Net income
|
-
|
-
|
-
|
136,310
|
136,310
|
|||||||||||||||
Balance as of December 31, 2023
|
29,013,834
|
139,694
|
(3,325
|
)
|
614,383
|
750,752
|
||||||||||||||
Issuance of shares upon exercise of options
|
58,217
|
160
|
-
|
-
|
160
|
|||||||||||||||
Issuance of shares upon vesting of RSU
|
212,653
|
-
|
-
|
-
|
-
|
|||||||||||||||
Issuance of shares upon conversion of convertible senior notes
|
154,215
|
(112
|
)
|
-
|
-
|
(112
|
)
|
|||||||||||||
Share based compensation
|
-
|
25,209
|
-
|
-
|
25,209
|
|||||||||||||||
Shares repurchase at cost
|
(160,518
|
)
|
(30,000
|
)
|
-
|
-
|
(30,000
|
)
|
||||||||||||
Other comprehensive loss
|
-
|
-
|
(1,976
|
)
|
-
|
(1,976
|
)
|
|||||||||||||
Net income
|
-
|
-
|
-
|
183,762
|
183,762
|
|||||||||||||||
Balance as of December 31, 2024
|
29,278,401
|
134,951
|
(5,301
|
)
|
798,145
|
927,795
|
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Net income
|
183,762
|
136,310
|
140,213
|
|||||||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||||||
Depreciation of property, plant and equipment
|
11,736
|
10,344
|
8,621
|
|||||||||
Amortization of intangible assets
|
5,643
|
5,857
|
6,033
|
|||||||||
Amortization of premium and accretion of discount on marketable securities, net
|
(7,178
|
)
|
(3,001
|
)
|
1,666
|
|||||||
Amortization of debt issuance costs
|
1,280
|
1,284
|
1,282
|
|||||||||
Share-based compensation
|
25,209
|
18,286
|
16,647
|
|||||||||
Net effect of exchange rate fluctuation
|
3,025
|
1,754
|
4,523
|
|||||||||
Changes in assets and liabilities:
|
||||||||||||
Trade accounts receivables, net
|
(29,051
|
)
|
(1,183
|
)
|
(31,634
|
)
|
||||||
Inventories
|
(23,897
|
)
|
(26,000
|
)
|
(29,311
|
)
|
||||||
Other current and long-term assets
|
(9,671
|
)
|
(5,752
|
)
|
(4,223
|
)
|
||||||
Deferred tax assets, net
|
(9,722
|
)
|
(6,241
|
)
|
(13,740
|
)
|
||||||
Operating lease right-of-use assets
|
3,668
|
3,050
|
3,873
|
|||||||||
Trade accounts payables
|
17,506
|
(7,807
|
)
|
5,142
|
||||||||
Deferred revenues
|
34,553
|
11,391
|
15,243
|
|||||||||
Operating lease liabilities
|
(3,938
|
)
|
(3,221
|
)
|
(6,351
|
)
|
||||||
Other current and long-term liabilities
|
32,299
|
(11,352
|
)
|
1,509
|
||||||||
Accrued severance pay, net
|
42
|
(188
|
)
|
46
|
||||||||
Net cash provided by operating activities
|
235,266
|
123,531
|
119,539
|
|||||||||
Cash flows from investment activities:
|
||||||||||||
Acquisition of subsidiary, net of acquired cash
|
-
|
-
|
(78,469
|
)
|
||||||||
Change in short-term and long-term interest-bearing bank deposits
|
(93,595
|
)
|
(29,658
|
)
|
129,944
|
|||||||
Investment in marketable securities
|
(271,987
|
)
|
(273,572
|
)
|
(211,742
|
)
|
||||||
Proceed from maturities of marketable securities
|
243,361
|
192,585
|
80,391
|
|||||||||
Proceed from sales of marketable securities
|
3,036
|
2,502
|
934
|
|||||||||
Purchase of property, plant and equipment
|
(17,215
|
)
|
(17,188
|
)
|
(21,314
|
)
|
||||||
Net cash used in investing activities
|
(136,400
|
)
|
(125,331
|
)
|
(100,256
|
)
|
||||||
Cash flows from financing activities:
|
||||||||||||
Settlement of a contingent consideration liability
|
-
|
-
|
(8,480
|
)
|
||||||||
Conversion of convertible senior notes
|
(18,506
|
)
|
- | - | ||||||||
Purchases of treasury shares
|
(30,000
|
)
|
(112
|
)
|
(21,416
|
)
|
||||||
Proceeds from exercise of options
|
160
|
122
|
90
|
|||||||||
Net cash provided by (used in) financing activities
|
(48,346
|
)
|
10
|
(29,806
|
)
|
|||||||
Effect of exchange rate fluctuations on cash, cash equivalents and restricted cash
|
(315
|
)
|
(2,357
|
)
|
(4,454
|
)
|
||||||
Decrease in cash, cash equivalents and restricted cash
|
50,205
|
(4,147
|
)
|
(14,977
|
)
|
|||||||
Cash and cash equivalents and restricted cash - beginning of year
|
107,574
|
111,721
|
126,698
|
|||||||||
Cash, cash equivalents and restricted cash - end of year
|
157,779
|
107,574
|
111,721
|
|||||||||
Supplemental disclosure of non-cash activities:
|
||||||||||||
Operating right-of-use assets recognized with corresponding operating lease liabilities
|
13,022
|
785
|
17,398
|
|||||||||
Accrued purchase of property, plant and equipment
|
7,248
|
70
|
699
|
|||||||||
Supplemental disclosure of cash flow information:
|
||||||||||||
Cash paid during the year for income taxes
|
29,876
|
26,842
|
23,014
|
Nova Ltd. (”Nova” or “the Parent Company”) was incorporated and commenced operations in 1993 in the design, development and production of process control systems, used in the manufacturing of semiconductors. Nova has wholly owned subsidiaries in the United States of America (the “U.S.”), Japan, Taiwan, Korea, China, Singapore and Germany (together defined as the “Company”).
The ordinary shares of the Company are traded on the NASDAQ Global Market since April 2000 and on the Tel-Aviv Stock Exchange since June 2002.
A. |
Principles of Consolidation and Basis of Presentation
|
B. |
Use of Estimates in the Preparation of Financial Statements
|
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. The Company's management evaluates its estimates on an ongoing basis, including those related to, but not limited to standalone selling price, allowance for credit losses related to marketable securities, inventory write-offs, business combination, fair value and useful lives of intangible assets, income taxes and tax uncertainties income taxes, credit loss related to collectability of trade accounts receivable, goodwill impairment, lease discount rate and lease period. These estimates are based on management's knowledge about current events and expectations about actions the Company may undertake in the future. Actual results could differ from those estimates.
C. |
Financial Statements in U.S. Dollars
|
D. |
Cash, Cash Equivalents and Restricted Cash
|
As of December 31,
|
||||||||||||
2024
|
2023
|
2022
|
||||||||||
Cash and cash equivalents
|
157,779
|
107,574
|
111,121
|
|||||||||
Long term restricted cash
|
-
|
-
|
600
|
|||||||||
Cash, cash equivalents and restricted cash
|
157,779
|
107,574
|
111,721
|
E. |
Short Term Bank Deposit
|
F. |
Marketable Securities
|
Investments in marketable securities are classified as available for sale at the time of purchase. Available for sale securities are carried at fair value based on quoted market prices, with unrealized gains and losses, reported in accumulated other comprehensive income (loss) in shareholders’ equity. Realized gains and losses on sales of marketable securities, are included in financial income, net. The amortized cost of marketable securities is adjusted for amortization of premium and accretion of discount to maturity, both of which, together with interest, are included in financial income, net.
G. |
Trade Accounts Receivables
|
H. |
Business Combination
|
I. |
Inventories
|
• |
Raw materials - using the moving average cost method, with specific items valued on a first-in, first-out (FIFO) basis.
|
• |
Service inventory, work in process and finished goods - using the moving average cost method, with specific items valued on a first-in, first-out (FIFO) and actual production cost basis (materials, labor and indirect manufacturing costs).
|
J. |
Property, Plant and Equipment
|
Years
|
|
Electronic equipment
|
3-7
|
Office furniture and equipment
|
3-17
|
Buildings
|
33
|
Leasehold improvements
|
Over the shorter of the term of the lease (including its extension periods) or the useful life of the asset
|
K. |
Goodwill and Intangible Assets
|
Weighted Average Useful Life (Years)
|
||
Technology
|
3-9
|
|
Customer relationships
|
10-13
|
L. |
Implementation costs incurred in cloud computing arrangement that is a service contract:
|
M. |
Impairment of Long-Lived Assets
|
N. |
Accrued Warranty Costs
|
O. |
Derivative Financial Instruments
|
P. |
Leases
|
Q. |
Convertible Senior Notes
|
R. |
Revenue Recognition
|
S. |
Research and Development
|
T. |
Income Taxes
|
U. |
Share-Based Compensation
|
V. |
Earnings per Share
|
Net income per share is shown below (U.S. dollars and share data in thousands, except per share data):
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Net income for basic earnings per share
|
183,762
|
136,310
|
140,213
|
|||||||||
Amortization of debt issuance costs related to the Convertible Notes, net of tax
|
1,109
|
1,130
|
1,128
|
|||||||||
Net income for diluted earnings per share
|
184,871
|
137,440
|
141,341
|
|||||||||
Basic weighted-average shares outstanding
|
29,113
|
28,828
|
28,697
|
|||||||||
Dilutive effect of share-based compensation
|
393
|
580
|
492
|
|||||||||
Dilutive effect of Convertible Senior Notes
|
2,632
|
2,681
|
2,681
|
|||||||||
Diluted weighted average shares outstanding
|
32,138
|
32,089
|
31,870
|
|||||||||
Earnings per share:
|
||||||||||||
Basic
|
6.31
|
4.73
|
4.89
|
|||||||||
Diluted
|
5.75
|
4.28
|
4.43
|
W. |
Concentrations of Credit Risk
|
X. |
Fair Value Measurements
|
Y. |
New Accounting Pronouncements
|
Matures within one year:
|
Matures after one year:
|
Total
|
||||||||||||||||||||||||||
Corporate
|
Governmental
|
Corporate
|
Governmental
|
|
||||||||||||||||||||||||
bonds
|
bonds
|
Total
|
bonds
|
bonds
|
Total
|
|||||||||||||||||||||||
Unrealized Gain
|
||||||||||||||||||||||||||||
Amortized Cost
|
125,296
|
39,220
|
164,516
|
66,989
|
20,912
|
87,901
|
252,417
|
|||||||||||||||||||||
Unrealized Gain
|
218
|
75
|
293
|
395
|
90
|
485
|
778
|
|||||||||||||||||||||
Fair Value
|
125,514
|
39,295
|
164,809
|
67,384
|
21,002
|
88,386
|
253,195
|
|||||||||||||||||||||
Unrealized Loss Less
|
||||||||||||||||||||||||||||
than 12 months
|
||||||||||||||||||||||||||||
Amortized Cost
|
23,535
|
3,026
|
26,561
|
108,786
|
16,620
|
125,406
|
151,967
|
|||||||||||||||||||||
Unrealized Loss
|
(10
|
)
|
(5
|
)
|
(15
|
)
|
(871
|
)
|
(92
|
)
|
(963
|
)
|
(978
|
)
|
||||||||||||||
Fair Value
|
23,525
|
3,021
|
26,546
|
107,915
|
16,528
|
124,443
|
150,989
|
|||||||||||||||||||||
Unrealized Loss
|
||||||||||||||||||||||||||||
12 Months or Greater
|
||||||||||||||||||||||||||||
Amortized Cost
|
23,774
|
2,043
|
25,817
|
13,314
|
-
|
13,314
|
39,131
|
|||||||||||||||||||||
Unrealized Loss
|
(261
|
)
|
(1
|
)
|
(262
|
)
|
(325
|
)
|
-
|
(325
|
)
|
(587
|
)
|
|||||||||||||||
Fair Value
|
23,513
|
2,042
|
25,555
|
12,989
|
-
|
12,989
|
38,544
|
|||||||||||||||||||||
Total
|
172,552
|
44,358
|
216,910
|
188,288
|
37,530
|
225,818
|
442,728
|
Matures within one year:
|
Matures after one year:
|
Total
|
||||||||||||||||||||||||||
Corporate
|
Governmental
|
|
Corporate
|
Governmental
|
||||||||||||||||||||||||
bonds
|
bonds
|
Total
|
bonds
|
bonds
|
Total
|
|||||||||||||||||||||||
Unrealized Gain
|
||||||||||||||||||||||||||||
Amortized Cost
|
32,622
|
37,808
|
70,430
|
94,175
|
22,780
|
116,955
|
187,385
|
|||||||||||||||||||||
Unrealized Gain
|
54
|
43
|
97
|
620
|
58
|
678
|
775
|
|||||||||||||||||||||
Fair Value
|
32,676
|
37,851
|
70,527
|
94,795
|
22,838
|
117,633
|
188,160
|
|||||||||||||||||||||
Unrealized Loss Less
|
||||||||||||||||||||||||||||
than 12 months
|
||||||||||||||||||||||||||||
Amortized Cost
|
55,007
|
1,025
|
56,032
|
38,169
|
2,023
|
40,192
|
96,224
|
|||||||||||||||||||||
Unrealized Loss
|
(74
|
)
|
(1
|
)
|
(75
|
)
|
(153
|
)
|
(14
|
)
|
(167
|
)
|
(242
|
)
|
||||||||||||||
Fair Value
|
54,933
|
1,024
|
55,957
|
38,016
|
2,009
|
40,025
|
95,982
|
|||||||||||||||||||||
Unrealized Loss
|
||||||||||||||||||||||||||||
12 Months or Greater
|
||||||||||||||||||||||||||||
Amortized Cost
|
79,038
|
11,991
|
91,029
|
35,108
|
-
|
35,108
|
126,137
|
|||||||||||||||||||||
Unrealized Loss
|
(1,161
|
)
|
(94
|
)
|
(1,255
|
)
|
(1,415
|
)
|
-
|
(1,415
|
)
|
(2,670
|
)
|
|||||||||||||||
Fair Value
|
77,877
|
11,897
|
89,774
|
33,693
|
-
|
33,693
|
123,467
|
|||||||||||||||||||||
Total
|
165,486
|
50,772
|
216,258
|
166,504
|
24,847
|
191,351
|
407,609
|
NOTE 4 - INVENTORIES
A. |
Composition:
|
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Raw materials
|
43,965
|
50,156
|
||||||
Service inventory
|
36,232
|
31,407
|
||||||
Work in process
|
37,036
|
31,873
|
||||||
Finished goods
|
39,366
|
24,762
|
||||||
156,599
|
138,198
|
B. |
In the years ended December 31, 2024, 2023 and 2022, the Company wrote down inventories in a total amount of $7,821, $8,748 and $6,406, respectively.
|
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Prepaid expenses
|
10,732
|
10,999
|
||||||
Governmental institutions
|
6,832
|
3,682
|
||||||
Governments grants receivables
|
782
|
662
|
||||||
Hedging derivative
|
617
|
1,229
|
||||||
Other
|
503
|
512
|
||||||
19,466
|
17,084
|
NOTE 6 - PROPERTY AND EQUIPMENT, NET
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Cost:
|
||||||||
Electronic equipment
|
66,304
|
72,116
|
||||||
Office furniture and equipment
|
6,105
|
6,322
|
||||||
Leasehold improvements
|
41,135
|
39,875
|
||||||
Land and building
|
26,683
|
11,673
|
||||||
140,227
|
129,986
|
|||||||
Accumulated depreciation:
|
||||||||
Electronic equipment
|
41,280
|
49,765
|
||||||
Office furniture and equipment
|
4,461
|
3,548
|
||||||
Leasehold improvements
|
12,701
|
9,799
|
||||||
Land and building
|
39
|
-
|
||||||
58,481
|
63,112
|
|||||||
Net book value
|
81,746
|
66,874
|
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Original amount:
|
||||||||
Technology
|
35,054
|
58,227
|
||||||
Customer relationships
|
3,834
|
9,747
|
||||||
38,888
|
67,974
|
|||||||
Accumulated amortization:
|
||||||||
Technology
|
6,934
|
22,955
|
||||||
Customer relationships
|
496
|
5,835
|
||||||
7,430
|
28,790
|
|||||||
Net book value
|
31,458
|
39,184
|
|
Year ended December 31,
|
|||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Technology
|
5,284
|
5,430
|
5,426
|
|||||||||
Customer relationships
|
359
|
427
|
607
|
|||||||||
5,643
|
5,857
|
6,033
|
Year ending December 31,
|
||||
2025
|
4,428
|
|||
2026
|
4,428
|
|||
2027
|
4,428
|
|||
2028
|
4,428
|
|||
2029
|
4,428
|
|||
2030 and thereafter
|
9,318
|
|||
Total
|
31,458
|
A. | Consists of: |
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Accrued salaries and fringe benefits
|
41,024
|
27,105
|
||||||
Accrued warranty costs (See B below)
|
11,238
|
8,080
|
||||||
Governmental institutions
|
14,282
|
4,846
|
||||||
Governments grants payables
|
1,230
|
1,019
|
||||||
Other
|
259
|
244
|
||||||
68,033
|
41,294
|
B. | Accrued Warranty Costs: |
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Other current liabilities
|
11,238
|
8,080
|
||||||
Other long-term liabilities
|
564
|
443
|
||||||
11,802
|
8,523
|
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Balance as of beginning of year
|
8,523
|
10,630
|
||||||
Services provided under warranty
|
(14,437
|
)
|
(11,764
|
)
|
||||
Changes in provision
|
17,716
|
9,657
|
||||||
Balance as of end of year
|
11,802
|
8,523
|
1. |
During any calendar quarter commencing after the calendar quarter ending on March 31, 2021 (and only during such calendar quarter), if the last reported sale price of the Company’s ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
|
2. |
During the five business day period after any 10 consecutive trading day period (“measurement period”) in which the trading price, determined pursuant to the terms of the Convertible Notes, per $1,000 principal amount of Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the ordinary shares and the conversion rate on each such trading day;
|
3. |
If the Company calls such Convertible Notes for redemption in certain circumstances, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or
|
4. |
Upon the occurrence of specified corporate events.
|
As of December 31, 2023, condition 1 as stated above has been met, as the Company share price exceeded the abovementioned threshold. During the calendar quarter ending on March 31, 2024, the Notes are therefore convertible. Consequently, as of December 31, 2023, the Notes are classified as current liability
• |
An increase of $12,075 to liability for convertible senior notes, in the consolidated balance sheets, to reflect the full principal amount of the convertible notes outstanding net of issuance costs.
|
• |
A reduction of $13,770 to additional paid-in capital, net of estimated income tax effects, to remove the equity component separately recorded for the conversion features associated with the convertible notes.
|
• |
An increase to deferred tax assets, net of $1,444, to reflect the decrease in deferred tax liability relating to removal of the equity component stated above.
|
• |
A cumulative-effect adjustment of $3,139, net of estimated income tax effects, to the balance of retained earnings.
|
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Principal amount
|
181,495
|
200,000
|
||||||
Unamortized issuance costs
|
(931
|
)
|
(2,322
|
)
|
||||
Net carrying amount
|
180,564
|
197,678
|
NOTE 11 - LEASES
Year
|
||||
2025
|
7,127
|
|||
2026
|
6,510
|
|||
2027
|
6,174
|
|||
2028
|
5,870
|
|||
2029
|
5,028
|
|||
2030 and thereafter
|
41,903
|
|||
Total lease payments
|
72,612
|
|||
Less imputed interest
|
(17,080
|
)
|
||
Total
|
55,532
|
A. |
Rights of Shares:
|
B. |
Share Repurchase:
|
C. |
Equity Based Incentive Plans:
|
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Cost of Revenues:
|
||||||||||||
Product
|
4,113
|
3,193
|
2,456
|
|||||||||
Service
|
2,900
|
1,753
|
1,710
|
|||||||||
Research and Development
|
11,179
|
7,736
|
6,861
|
|||||||||
Sales and Marketing
|
4,864
|
3,437
|
3,179
|
|||||||||
General and Administrative
|
2,153
|
2,167
|
2,441
|
|||||||||
Total
|
25,209
|
18,286
|
16,647
|
During 2024, 2023 and 2022, the Company did not grant share options.
2024
|
||||||||
Share
Options
|
Weighted
Average
Exercise Price
|
|||||||
Outstanding - beginning of year
|
106,279
|
31.04
|
||||||
Exercised
|
(58,217
|
)
|
27.91
|
|||||
Cancelled
|
(9,512
|
)
|
32.31
|
|||||
Outstanding - year end
|
38,550
|
35.45
|
||||||
Options exercisable at year end
|
37,830
|
34.18
|
The weighted-average remaining contractual term of options outstanding at year end is 1.628.
Range of
Exercise Prices
|
Number
Outstanding
|
Weighted
Average
Remaining
Contractual
Life
|
Weighted
Average
Exercise Price
|
Number
Exercisable
|
Weighted
Average
Exercise Price
|
|||||||||||||||||
(US dollars)
|
(in years)
|
(US dollars)
|
(US dollars)
|
|||||||||||||||||||
20.00-35.00
|
24,509
|
1.16
|
24.84
|
24,509
|
24.84
|
|||||||||||||||||
35.01-50.00
|
9,845
|
2.41
|
43.44
|
9,845
|
43.44
|
|||||||||||||||||
50.01-70.00
|
2,036
|
2.58
|
53.61
|
2,036
|
53.61
|
|||||||||||||||||
70.01-102.35
|
2,160
|
2.48
|
102.35
|
1,440
|
102.35
|
|||||||||||||||||
38,550
|
35.45
|
37,830
|
34.18
|
2024
|
||||||||
Number
of RSUs
|
Weighted
average
grant date
fair value
(USD)
|
|||||||
Unvested - beginning of year
|
587,669
|
98.39
|
||||||
Granted
|
136,736
|
196.83
|
||||||
Vested
|
(212,653
|
)
|
93.93
|
|||||
Canceled
|
(15,216
|
)
|
98.34
|
|||||
Unvested at year end
|
496,536
|
127.39
|
A. |
Israeli Taxation
|
1. |
The tax rate on a company in Development area A, effective January 1, 2014 is 9% (instead of 7% in 2014 and 6% in 2015 and thereafter), and the tax rate for companies in all other areas will be 16% (instead of 12.5% in 2014 and 12% in 2015 and thereafter).
|
2. |
The tax rate on dividend distributed, generated from "preferred income" or by a company that has an approved enterprise increased effective January 1, 2014 from 15% to 20%.
|
B. |
U.S. Taxation
|
C. | Deferred Taxes: |
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Deferred tax assets:
|
||||||||
Net operating loss carryforwards
|
346
|
412
|
||||||
Tax credits carryforward
|
3,198
|
2,872
|
||||||
Reserve and allowances
|
12,872
|
9,853
|
||||||
Operating lease liabilities
|
5,704
|
2,494
|
||||||
Research and development
|
20,649
|
14,842
|
||||||
Gross tax assets
|
42,769
|
30,473
|
||||||
Valuation allowance
|
(3,574
|
)
|
(2,790
|
)
|
||||
Total tax assets
|
39,195
|
27,683
|
||||||
Deferred tax liabilities:
|
||||||||
Intangible assets acquired in business combination
|
(9,399
|
)
|
(11,346
|
)
|
||||
Operating lease right-of-use assets
|
(5,102
|
)
|
(1,936
|
)
|
||||
Reserve and allowances
|
(1,550
|
)
|
(1,392
|
)
|
||||
Total deferred tax liabilities
|
(16,051
|
)
|
(14,674
|
)
|
||||
Net deferred tax assets
|
23,144
|
13,009
|
Year ended December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Deferred tax assets
|
31,639
|
23,583
|
||||||
Deferred tax liabilities
|
(8,495
|
)
|
(10,574
|
)
|
||||
23,144
|
13,009
|
Year ended December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
Domestic
|
9,201
|
7,855
|
||||||
Foreign
|
13,943
|
5,154
|
||||||
23,144
|
13,009
|
D. |
Income before taxes on income included in the consolidated statements of operations:
|
|
Year ended December 31,
|
|||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Domestic
|
138,270
|
117,936
|
121,076
|
|||||||||
Foreign (mainly US and Germany)
|
78,017
|
36,763
|
37,333
|
|||||||||
216,287
|
154,699
|
158,409
|
E. |
Income tax expenses (tax benefits) included in the consolidated statements of operations:
|
Year ended December 31, |
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Domestic
|
20,268
|
17,363
|
15,868
|
|||||||||
Foreign (mainly US and Germany)
|
12,257
|
1,026
|
2,328
|
|||||||||
32,525
|
18,389
|
18,196
|
||||||||||
Current
|
42,488
|
24,845
|
32,323
|
|||||||||
Deferred
|
(9,963
|
)
|
(6,456
|
)
|
(14,127
|
)
|
||||||
32,525
|
18,389
|
18,196
|
F. | Tax Reconciliation: |
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Income before taxes on income
|
216,287
|
154,699
|
158,409
|
|||||||||
Statutory tax expenses
|
25,954
|
18,564
|
19,009
|
|||||||||
Effect of non-benefited income New Technological or Preferred Enterprises statuses in Israel
|
(66
|
)
|
657
|
335
|
||||||||
Permanent differences, including difference between the basis of measurement of income reported for tax purposes and the basis of measurement of income for financial reporting purposes, net
|
(162
|
)
|
(384
|
)
|
(1,131
|
)
|
||||||
Change in tax reserve for uncertain tax positions
|
3,865
|
(625
|
)
|
(51
|
)
|
|||||||
Effect of foreign operations taxed at various rates
|
8,512
|
4,070
|
3,477
|
|||||||||
Foreign Derived Intangible Income benefit
|
(3,559
|
)
|
(2,497
|
)
|
(2,483
|
)
|
||||||
Tax credits
|
(2,553
|
)
|
(1,801
|
)
|
(1,640
|
)
|
||||||
Adjustments for previous year’s tax
|
(315
|
)
|
(651
|
)
|
(172
|
)
|
||||||
Change in valuation allowance
|
784
|
871
|
692
|
|||||||||
Other
|
65
|
185
|
160
|
|||||||||
6,571
|
(175
|
)
|
(813
|
)
|
||||||||
Actual tax expenses
|
32,525
|
18,389
|
18,196
|
G. |
Effective Tax Rates:
|
H. |
Tax Assessments:
|
I. |
Undistributed earnings of foreign subsidiaries:
|
J. |
Uncertain Tax Positions:
|
As of December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Balance at the beginning of the year
|
9,422
|
9,276
|
8,674
|
|||||||||
Increase (decrease) related to prior year tax positions
|
3
|
(2,884
|
)
|
(1,202
|
)
|
|||||||
Increase related to current year tax positions
|
4,356
|
3,030
|
1,804
|
|||||||||
Balance at the end of the year*
|
13,781
|
9,422
|
9,276
|
K. | Income from Other Sources in Israel: |
A. |
Segments
|
B. |
Sales by Geographic Area (as Percentage of Total Sales):
|
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
%
|
%
|
%
|
||||||||||
China
|
39
|
36
|
28
|
|||||||||
Taiwan, R.O.C.
|
20
|
18
|
32
|
|||||||||
Korea
|
18
|
20
|
13
|
|||||||||
USA
|
14
|
13
|
16
|
|||||||||
Other
|
9
|
13
|
11
|
|||||||||
Total
|
100
|
100
|
100
|
C. |
Sales by Major Customers (as Percentage of Total Sales): |
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
%
|
%
|
%
|
||||||||||
Customer A
|
18
|
19
|
12
|
|||||||||
Customer B
|
14
|
18
|
23
|
D. |
Long-lived assets by geographic location:
|
As of December 31,
|
||||||||
2 0 2 4
|
2 0 2 3
|
|||||||
%
|
%
|
|||||||
Israel
|
48
|
62
|
||||||
US
|
24
|
19
|
||||||
Germany
|
22
|
13
|
||||||
Other
|
6
|
6
|
||||||
Total long-lived assets (*)
|
100
|
100
|
A. |
Hedging Activities
|
B. |
Derivative Instruments
|
Derivative Assets
Reported in Other
Current Assets
|
Derivative Liabilities
Reported in Other
Current Liabilities
|
|||||||||||||||
December 31,
|
December 31,
|
|||||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 4
|
2 0 2 3
|
|||||||||||||
Derivatives designated as hedging instruments in cash flow hedge
|
617
|
1,229
|
-
|
-
|
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Cost of revenues:
|
||||||||||||
Products
|
(29
|
)
|
268
|
254
|
||||||||
Services
|
(10
|
)
|
94
|
91
|
||||||||
Total cost of revenues
|
(39
|
)
|
365
|
345
|
||||||||
Operating expenses:
|
||||||||||||
Research and development, net
|
(66
|
)
|
599
|
870
|
||||||||
Sales and marketing
|
(19
|
)
|
158
|
163
|
||||||||
General and administrative
|
(49
|
)
|
457
|
435
|
||||||||
Total operating expenses
|
(134
|
)
|
1,214
|
1,468
|
||||||||
Loss (gain) on derivative instruments
|
(173
|
)
|
1,576
|
1,813
|
Year ended December 31,
|
||||||||||||
2 0 2 4
|
2 0 2 3
|
2 0 2 2
|
||||||||||
Interest income
|
34,547
|
22,643
|
6,478
|
|||||||||
Amortization of issuance costs related to the Convertible Senior Notes (Note 10)
|
(1,280
|
)
|
(1,284
|
)
|
(1,282
|
)
|
||||||
Exchange rate gain (loss), net
|
(4,186
|
)
|
1,303
|
3,469
|
||||||||
Bank charges
|
(334
|
)
|
(226
|
)
|
(187
|
)
|
||||||
Total
|
28,747
|
22,436
|
8,478
|
Number |
Description |
101.INS |
Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document |
101.SCH |
Inline XBRL Taxonomy Extension Schema |
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase |
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase |
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase |
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase |
104 |
Cover page formatted as Inline XBRL and contained in Exhibit 101 |
NOVA LTD. |
||
By: |
/s/ Gabriel Waisman
Gabriel Waisman
President and Chief Executive Officer
|
1 |
|
2 |
|
2 |
|
2 |
|
2 |
|
3 |
|
3 |
|
3 |
|
3 |
|
4 |
|
4 |
|
5 |
|
5 |
|
5 |
|
6 |
|
6 |
|
6 |
|
6 |
|
6 |
|
7 |
|
7 |
|
8 |
|
8 |
|
8 |
|
8 |
|
8 |
|
9 |
|
9 |
|
9 |
|
10 |
|
10 |
|
10 |
|
10 |
|
11 |
|
11 |
|
11 |
|
11 |
|
11 |
|
11 |
|
12 |
|
12 |
|
12 |
|
12 |
|
12 |
|
12 |
|
13 |
1. |
In these Articles the following terms shall bear the meanings set opposite to them, unless inconsistent with the subject or context:
|
Articles |
These Amended and Restated Articles of Association as may be amended from time to time.
|
Auditor |
As defined under the Law.
|
Board |
The Board of Directors of the Company.
|
CEO |
Chief Executive Officer, also referred to under the Law as the general manager.
|
Class Meeting |
A meeting of the holders of a class of shares.
|
Chairman |
Chairman of the Board.
|
Company |
Nova Ltd.
|
Companies Regulations |
All regulations promulgated from time to time under the Companies Law.
|
Distribution |
As defined under the Law.
|
External Director |
As defined under the Law.
|
The Law or the Companies Law |
The Israeli Companies Law, 5759 - 1999 and the Companies Regulations.
|
NIS |
New Israeli Shekel
|
The Office |
The registered office of the Company as may be re-located from time to time.
|
Office Holder |
As defined under the Law.
|
Ordinary Shares |
The Company’s Ordinary Shares, with no par value.
|
Register |
Shareholders Register maintained by or on behalf of the Company.
|
Shareholder |
As defined under the Law.
|
Simple Majority |
A majority of more than fifty percent (50%) of the votes cast by those Shareholders present and voting, not taking into consideration abstaining votes.
|
The Statutes |
The Law, the Israeli Companies Ordinance (New Version) 1983, the Securities Law, 5738 - 1968 (the “Securities Law”) and all applicable laws and regulations applicable in any
relevant jurisdiction (including without limitation U.S. Federal laws and regulations), and rules of any stock market in which the Company’s shares are registered for trading as shall be in force from time to time and to the extent applicable
to the Company.
|
2. |
Words importing the singular shall include the plural, and vice-versa. Words importing the masculine gender shall include the feminine gender; and words importing persons shall
include corporate bodies.
|
3. |
The name of the Company is Nova Ltd.
|
4. |
The purposes of the Company shall be to engage in the types of pursuits specified below:
|
|
4.1. |
To invent, design, plan, develop, manufacture, market and trade in the field of measuring instruments in electronics, micro-electronics, medicine, chemistry, metallurgy,
ceramics, and any other field.
|
|
4.2. |
To initiate, participate, manage, execute, import and export any kind of project within the boarders of the State of Israel and/or outside Israel.
|
|
4.3. |
To register patents, trademarks, trade names, intellectual property rights marketing rights and any other right of any kind whatsoever, both in Israel and abroad.
|
|
4.4. |
To engage in any legal activity, both in Israel and abroad.
|
4A. |
The Company’s headquarters shall be located in Israel, unless the Board shall otherwise resolve, by a resolution approved by at least 75% of the members of the Board then in
office.
|
5. |
The Company is a public company pursuant to the Companies Law.
|
6. |
The liability of each Shareholder for the Company's debts is limited to the full payment of the original issue price of the shares first allotted to such Shareholder or his
predecessors. Once such price is paid by the original owner of shares, there is no further liability of the holder and such holder’s transferees for the Company’s debts.
|
7. |
The registered share capital of the Company shall consist of 60,000,000 (sixty million) Ordinary Shares with no par value.
|
8. |
All issued and outstanding shares of the Company of the same class are of equal rights between them for all intents and purposes concerning the rights set forth below.
|
9. |
Each issued Ordinary Share entitles its holder to the rights as described below:
|
|
9.1. |
The equal right to participate in and vote at the Company's general meetings, whether ordinary meetings or special meetings, and each of the shares in the Company shall entitle
the holder thereof, who is present at the meeting and participating in the vote, whether in person, or by proxy, to one vote.
|
|
9.2. |
The equal right to participate in any Distribution.
|
|
9.3. |
The equal right to participate in the distribution of assets available for distribution in the event of liquidation of the Company.
|
10. |
If two or more persons are registered as joint holders of any shares, any one of such persons may give effectual receipts for any dividend or other monies in respect of such
share and his or her confirmation will bind all holders of such share.
|
11. |
[Reserved].
|
12. |
A Shareholder shall not be entitled to rights as a Shareholder, including the right to dividends, unless said Shareholder fully paid all sums in accordance with the conditions
of the allocation, including interest, linkage and expenses, if any, and all unless otherwise determined in the conditions of the allocation.
|
13. |
A shareholder who is registered in the Register is entitled to receive from the Company, without payment and at such shareholder’s request, within a period of three months after
the allocation or registration of the transfer, one share certificate with respect to all the shares registered in his name, which shall specify the aggregate number of the shares held by such shareholder. In the event of a jointly held
share, the Company shall issue one share certificate for all the joint holders of the share, and the delivery of such certificate to one of the joint holders shall be deemed to be delivery to all of them. Every certificate shall bear the
Company’s seal or a facsimile copy thereof and be signed by two Office Holders of the Company, or one director and the Company's secretary or by any other person appointed by the Board for such purpose.
|
14. |
The Company may issue a new certificate in lieu of a certificate that was issued
and was lost, defaced, or destroyed, on the basis of such proof and guarantees as the Company may require, and after payment of an amount that shall be prescribed by the Company, and the Company may also replace existing certificates with new
certificates, free of charge, subject to such conditions as the Company shall stipulate.
|
15. |
Except as otherwise provided in these Articles, the Company shall be entitled to treat the registered holder of any share as the absolute owner thereof, and, accordingly, shall
not, except as ordered by a court of competent jurisdiction, or as required by statute, be bound to recognize any equitable or other claim to, or interest in such share on the part of any other person.
|
16. |
To the extent required by the Law a trustee must inform the Company of the fact that such trustee is holding shares of the Company in trust for another person at such time as
may be required by the Law. The Company shall register that fact in the Register in respect of such shares. The trustee shall be deemed to be the sole holder of said shares.
|
17. |
Subject to the Statutes, and subject to any applicable agreements or undertakings of any specific shareholder, the shares shall be freely transferable.
|
18. |
Transfer of registered shares shall be made in writing or any other manner, in a form specified by the Board or the transfer agent appointed by the Company, and such transfer
form should be signed by both the transferee and the transferor and delivered to the Office or to such transfer agent, together with the certificates of the shares due to be transferred, if such certificates have been issued. The transferee
shall be deemed to be the shareholder with respect to the transferred shares only from the date of registration of his name in the Register.
|
19. |
The Board may close the Register and suspend the registration of transfers for such period of time as the Board shall deem fit, provided that the period of closure of any such
book shall not exceed 30 days each year. The Company shall notify the shareholders of such decision.
|
20. |
In the case of the death, liquidation, bankruptcy, dissolution, winding-up or a similar occurrence of a Shareholder, the legal successors of such Shareholder shall be the only
persons recognized by the Company as having any title to such shares, but nothing herein contained shall release the estate of the predecessor from any liability in respect of such shares.
|
21. |
The legal successors may, upon producing such evidence of title as the Board shall require, be registered themselves as holders of the shares, or subject to the provisions as to
transfers herein contained, transfer the same to some other person.
|
22. |
(a) Subject to the Statutes, a general meeting of shareholders may from time to time resolve to:
|
|
(1) |
Alter or add classes of shares that shall constitute the Company's authorized capital, including shares with preference rights, deferred rights, conversion rights or any other
special rights or limitations.
|
|
(2) |
Increase the Company's registered share capital by creating new shares either of an existing class or of a new class.
|
|
(3) |
Consolidate and/or split all or any of its share capital.
|
|
(4) |
Cancel any registered shares not yet allocated, provided that the Company has made no commitment to allocate such shares.
|
|
(5) |
Reduce the Company’s share capital and any reserved fund for redemption of capital.
|
|
(1) |
Determine that fractions of shares that do not entitle their owners to a whole Share, will be sold by the Company and that the consideration for the sale be paid to the
beneficiaries, on terms the Board may determine;
|
|
(2) |
Allot to every Shareholder, who holds a fraction of a Share resulting from a consolidation and/or split, shares of the class that existed prior to the consolidation and/or
split, in a quantity that, when consolidated with the fraction, will constitute a whole Share, and such allotment will be considered valid immediately prior to the consolidation or split;
|
|
(3) |
Determine the manner for paying the amounts to be paid for shares allotted in accordance with Article 22(c)(2) above, including on account of bonus shares; and/or
|
|
(4) |
Determine that the owners of fractions of shares will not be entitled to receive a whole Share in respect of a Share fraction.
|
23. |
Except as otherwise provided by or pursuant to these Articles or by the conditions of issue, any new share capital shall be considered as part of the original share capital, and
shall be subject to the same provisions of these Articles with reference to payment of calls, lien, transfer, transmission, forfeiture and otherwise, which applies to the original share capital.
|
24. |
If at any time the share capital is divided into different classes of shares, any change to the rights and privileges of the holders of any such class of shares shall require
the approval of a Class Meeting of such class of shares by a Simple Majority (unless otherwise provided by the Statutes or by the terms of issue of the shares of that class).
|
25. |
The rights and privileges of the holders of any class of shares shall not be deemed to have been altered by creating or issuing shares of any class, including a new class
(unless otherwise provided by the terms of issue of the shares of that class).
|
26. |
The Company may, by resolution of the Board, from time to time, raise or borrow or secure the payment of any sum or sums of money for the purposes of the Company. The Company,
by resolution of the Board, may also raise or secure the payment or repayment of such sum or sums in such manner and upon such terms and conditions in all respects as it deems fit, and in particular by the issue of debentures or debenture
stock of the Company charged upon all or any part of the property of the Company (both present and future) including its unissued and/or its uncalled capital for the time being. Issuance of any series of debentures shall require Board
approval.
|
27. |
Annual general meetings shall be held at least once a calendar year, at such place and time as determined by the Board, but not later than fifteen (15) months after the last
annual general meeting. Such general meetings shall be called "Annual Meetings" and all other general meetings of the Company shall be called "Special Meetings". The Annual Meeting shall review the Company's financial statements and shall
transact any other business required pursuant to these Articles or to the Law, and any other matter as shall be determined by the Board. Annual Meetings and Special Meetings shall be convened in Israel, unless the Company’s headquarters shall
have been transferred to another country in accordance with the provisions of these Articles.
|
28. |
The Board may convene a Special Meeting by its resolution, and is required to convene a Special Meeting should it receive a request, in writing, from a person or persons
entitled, under the Companies Law, to request such meeting.
|
29. |
In addition, subject to the Law, the Board may accept a request of a Shareholder holding not less than the required percentage under the Companies Law of the voting rights at
the general meeting which entitles such Shareholder to require the Company to include a matter on the agenda of the general meeting, to include a subject in the agenda of a general meeting, provided that such subject is a proper subject for
action by shareholders under the Law and these Articles and only if the request also sets forth: (a) the name and address of the Shareholder making the request; (b) a representation that the Shareholder is a holder of record of shares of the
Company, holding not less than required percentage under the Law and intends to appear in person or by proxy at the meeting; (c) a description of all arrangements or understandings between the Shareholder and any other person or persons
(naming such person or persons) in connection with the subject which is requested to be included in the agenda; and (d) a declaration that all the information that is required under the Law and any other applicable law to be provided to the
Company in connection with such subject, if any, has been provided. In addition, if such subject includes a nomination to the Board in accordance with the Articles, the request shall also set forth the consent of each nominee to serve as a
director of the Company if so elected and a declaration signed by each nominee declaring that there is no limitation under the Law for the appointment of such nominee. Furthermore, the Board, may, in its discretion to the extent it deems
necessary, request that the Shareholders making the request provide additional information necessary so as to include a subject in the agenda of a general meeting, as the Board may reasonably require.
|
30. |
Subject to applicable law, the Board shall determine the agenda of any general meeting.
|
31. |
Unless otherwise required by the Law and these Articles, the Company is not required to give notice under section 69 of the Companies Law.
|
32. |
No business shall be transacted at any general meeting of the Company unless a quorum of Shareholders is present at the opening of the Meeting.
|
33. |
If within half an hour from the time appointed for the holding of a general meeting a quorum is not present, the general meeting shall stand adjourned one day thereafter at the
same time and place or to such other day, time and place as the Board may indicate in a notice to the Shareholders. At such adjourned Meeting any number of Shareholders shall constitute a quorum for the business for which the original Meeting
was called.
|
34. |
The Chairman shall preside as the chairman at every general meeting, but if there shall be no such Chairman or if at any meeting the Chairman shall not be present within fifteen
(15) minutes after the time appointed for holding the same, or shall be unwilling to act as chairman, then the Board members present at the meeting shall choose one of the Board members as chairman of the meeting and if they shall not do so
then the Shareholders present shall choose a Board member, or if no Board member be present or if all the Board members present decline to take the chair, they shall choose any other person present to be chairman of the meeting.
|
35. |
The chairman may, with the consent of a general meeting at which a quorum is present, and shall if so directed by the general meeting, adjourn any meeting, discussion or the
resolution with respect to a matter that is on the agenda, from time to time and from place to place as the meeting shall determine. Except as may be required by the Law, no Shareholder shall be entitled to any notice of an adjournment or of
the business to be transacted at an adjourned meeting. No business shall be transacted at any adjourned meeting other than the business which might have been transacted at the meeting from which the adjournment took place.
|
36. |
A vote in respect of the election of the chairman of the meeting or regarding a resolution to adjourn the meeting shall be carried out immediately. All other matters shall be
voted upon during the meeting at such time and order as decided by the chairman.
|
37. |
All resolutions proposed at any general meeting will require a Simple Majority, unless otherwise required by the Statutes or these Articles. Except as otherwise required by the
Statues or these Articles, alteration or amendment of these Articles shall require a Simple Majority. Notwithstanding anything in these Articles to the contrary, the provisions of Articles 4A, 27 (last sentence), 37, 50, 60(i) and 94 may only
be amended by a resolution at the general meeting of the Company, provided however, that such amendment was also approved by a resolution of at least 75% of the members of the Board then in office, at a session of the Board which has taken
place prior to the general meeting.
|
38. |
A declaration by the chairman of the meeting that a resolution has been carried, or has been carried unanimously or by a particular majority, or rejected, or not carried by a
particular majority and an entry to that effect in the minutes of the meeting shall be prima facie evidence thereof.
|
39. |
The chairman of the meeting will not have a second and/or a casting vote. If the vote is tied with regard to a certain proposed resolution such proposal shall be deemed
rejected.
|
40. |
If two or more persons are jointly entitled to a share, the vote of the senior one who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the
votes of the other registered holders of the share, and for this purpose seniority shall be determined by the order in which the names stand in the Register.
|
41. |
A proxy need not be a Shareholder of the Company.
|
42. |
The instrument appointing a proxy shall be in writing signed by the appointer or of his attorney-in-fact duly authorized in writing. A corporate entity shall vote by a
representative duly appointed in writing by such entity.
|
43. |
Unless otherwise determined by the Board, the instrument of appointment must be submitted to the Office no later than 48 hours prior to the first general meeting to be attended
by such proxy or representative. The instrument of appointment shall automatically terminate and cease to be of any force or affect on the anniversary (12 months) of the date of the instrument of appointment, unless such instrument sets out a
different expiry date.
|
44. |
A proxy may be appointed in respect of only some of the shares held by a Shareholder, and a Shareholder may appoint more than one proxy, each empowered to vote by virtue of a
portion of the shares.
|
45. |
A Shareholder being of unsound mind or pronounced to be unfit to vote by a competent court of law may vote through a legally appointed guardian or any other representative
appointed by a court of law to vote on behalf of such Shareholder.
|
46. |
A Shareholder entitled to vote may signify in writing his approval of, or dissent from, or may abstain from any resolution included in a proxy instrument furnished by the
Company. A proxy instrument may include resolutions pertaining to such issues which are permitted to be included in a proxy instrument according to the Statutes, and such other issues which the Board may decide, in a certain instance or in
general, to allow voting through a proxy. A Shareholder voting through a proxy instrument shall be taken into account in determining the presence of a quorum as if such Shareholder is present at the meeting.
|
47. |
The chairman of the general meeting shall be responsible for recording the minutes of the general meeting and any resolution adopted.
|
48. |
The provisions of these Articles relating to general meetings shall, mutatis mutandis, apply to Class Meetings.
|
49. |
The Board shall have and execute all powers and/or responsibilities allocated to the Board by the Statutes and these Articles, including setting the Company’s policies and
supervision over the execution of the powers and responsibilities of the CEO. The Board may execute any power of the Company that is not specifically allocated by the Statutes or by these Articles to another organ of the Company.
|
50. |
The number of directors on the Board shall be no less than five (5) but no more than nine (9) and, to the extent required under applicable law, shall include at least two
External Directors. The majority of the members of the Board shall be residents of Israel, unless the Company’s headquarters shall have been transferred to another country in accordance with the provisions of these Articles.
|
51. |
The directors of the Company shall be elected at each Annual Meeting by a Simple Majority and shall hold office until the end of the next Annual Meeting and so long as an Annual
Meeting is not convened, unless their office is vacated prior thereto in accordance with the provisions of these Articles and the Law. This Article shall not apply to the election and tenure of External Directors, in respect of whom the
provisions of the Law shall apply.
|
52. |
As long as the number of directors serving on the Board is less than the maximal number of directors under Article 50, the Board can act to appoint directors to the Board.
|
53. |
Should a director cease serving the remaining directors may continue to act, provided that their number shall be not less than the minimal number of directors mentioned under
Article 50 above. In the event the number of directors is less than the minimal number, the directors can act to appoint directors so the number of directors in office shall be equal to or higher than the minimal number mentioned under
Article 50 above or alternatively can act to call a Special Meeting to elect directors.
|
54. |
The appointment of a director by the Board shall be in effect until the next Annual Meeting or until he or she shall cease serving in office pursuant to the provisions of these
Articles.
|
55. |
The term of office of a director shall commence on the date of such director’s election by the general meeting or by the Board or on a later date, should such date be determined
in the resolution of appointment of the general meeting or of the Board.
|
56. |
The Company shall determine the remuneration of the directors, if any, in accordance with the Law.
|
57. |
The Board shall appoint one of its members to serve as the Chairman and may replace the Chairman from time to time. The Chairman shall preside at meetings of the Board, but if
at any meeting the Chairman is not present within fifteen (15) minutes after the time appointed for holding the meeting, the present directors shall choose a present director to be chairman of such meeting.
|
58. |
The directors shall meet together for the dispatch of business, adjourn and otherwise regulate their meetings as they deem fit, subject to these Articles.
|
59. |
No business shall be transacted at any meeting of the Board unless a quorum of directors is present when a meeting is called to order. A quorum shall be deemed to exist when
there are present personally or represented by an alternate director at least half of the directors then in office.
|
60. |
(i) A majority of the sessions of the Board (not including sessions held by use of means of communication) each year, but not less than four (4) sessions each year, shall be
convened in Israel, unless the Company’s headquarters shall have been transferred to another country in accordance with the provisions of these Articles; (ii) without derogating from sub-section (i) of this Article, some or all of the
directors may attend meetings of the Board through computer network, telephone or any other media of communication, enabling the directors to communicate with each other, in the deemed presence of all of them, provided that due prior notice
detailing the time and manner of holding a given meeting is served upon all the directors. The directors may waive the necessity of such notice either beforehand or retrospectively.
|
61. |
A resolution in writing signed by all of the directors eligible to participate in the discussion and vote on such resolution, or in respect of which all such directors have
agreed (in writing by mail, fax or electronic mail) not to convene, shall be as valid and effective for all purposes as if passed at a meeting of the Board duly convened and held.
|
62. |
While exercising his/her voting right, each director shall have one vote. Resolutions of the Board will be decided by a simple majority of the directors present and voting, not
taking into consideration abstaining votes, except as otherwise provided in these Articles or by the Statutes. In the event the vote is tied, the Chairman of the Board shall not have a casting vote, and such resolution shall be deemed
rejected.
|
63. |
Subject to the Law, a director shall be entitled at any time and from time to time to appoint in writing any person who is qualified to serve as a director, to act as his/her
alternate and to terminate the appointment of such person. The appointment of an alternate director does not negate the responsibility of the appointing director and such responsibility shall continue to apply to such appointing director -
taking into account the circumstances of the appointment.
|
64. |
The Board may set up committees and appoint members to these committees subject to the Statutes. A resolution passed or an act done by such a committee pursuant to an authority
granted to such committee by the Board shall be treated as a resolution passed or act done by the Board, unless expressly otherwise prescribed by the Board or the Statutes for a particular matter or in respect of a particular committee.
|
65. |
Meetings of committees and proceedings thereat (including the convening of the meetings, the election of the chairman and the votes) shall be governed by the provisions herein
contained for regulating the meetings and proceedings of the Board so far as the same are applicable thereto and unless otherwise determined by the Board, including by an adoption of a charter governing the committee proceedings.
|
66. |
[Reserved]
|
67. |
The resolutions of the Board shall be recorded in the Company's Minutes Book, as required under the Statutes, signed by the Chairman or the chairman of a certain meeting. Such
signed minutes shall be deemed prima facie evidence of the meeting and the resolutions resolved therein.
|
68. |
All acts done bona fide by any meeting of the Board or of a committee of the Board or by any person acting as a director, shall, notwithstanding it be afterwards discovered that
there was some defect in the appointment of any such director or person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such person had been duly appointed and was qualified to be a director.
|
69. |
The Board shall appoint at least one CEO, for such period and upon such terms as the Board deems fit.
|
70. |
The CEO shall have all managing and execution powers within the policies and guidelines set forth by the Board, and shall be under the supervision of the Board. The CEO may
delegate any of his powers to his subordinates, subject to the approval of the Board; (ii)
|
71. |
The Company may insure the liability of an Office Holder, to the fullest extent permitted under the Statutes.
|
72. |
Without derogating from the aforesaid, the Company may enter into a contract to insure the liability of an officer therein for an obligation imposed on him in consequence of an
act done in his capacity as an Office Holder, in any of the following cases:
|
|
72.1. |
A breach of the duty of care vis-a-vis the Company or vis-a-vis another person;
|
|
72.2. |
A breach of the fiduciary duty vis-a-vis the Company, provided that the Office Holder acted in good faith and had a reasonable basis to believe that the act would not harm the
Company, or in connection with a financial sanction;
|
|
72.3. |
A monetary obligation imposed on him in favor of another person;
|
|
72.4. |
Any other matter in respect of which it is permitted or will be permitted under applicable law to insure the liability of an Office Holder in the Company, including, without
limitation, matters referenced in Section 56H(b)(1) of the Securities Law.
|
73. |
The Company may indemnify an Office Holder, to the fullest extent permitted under the Statutes. Without derogating from the aforesaid, the Company may indemnify an Office Holder
for a liability or expense imposed on him in consequence of an act done in his capacity as an Office Holder in the Company, as follows:
|
|
73.1. |
A monetary obligation imposed on him or incurred by him in favor of another person pursuant to a judgment, including a judgment given in settlement or a court approved
settlement or arbitrator's award;
|
|
73.2. |
Reasonable legal fees, including attorney’s fees, incurred by an Office Holder in consequence of an investigation or proceeding filed against him by an authority that is
authorized to conduct such investigation or proceeding, provided that such investigation or proceeding (i) concludes without the filing of an indictment against the Office Holder or (ii) concluded with the imposition of a monetary payment on
the Office Holder in lieu of criminal proceedings, but the criminal offense in question does not require the proof of criminal intent, all within the meaning of the Law.
|
|
73.3. |
Reasonable litigation costs, including attorney’s fees, incurred by an Office Holder or which he is ordered to pay by a court, in proceedings filed against him by the Company or
on its behalf or by another person, or in a criminal charge of which he is acquitted, or in a criminal charge of which he is convicted of an offence that does not require proof of criminal intent.
|
|
73.4. |
Any other obligation or expense in respect of which it is permitted or will be permitted under the Statutes to indemnify an Office Holder, including, without limitation, matters
referenced in Section 56H(b)(1) of the Securities Law.
|
74. |
The Company may give an advance undertaking to indemnify an Office Holder therein in respect of the following matters:
|
|
74.1. |
Matters as detailed in Article 73.1, provided however, that the undertaking is restricted to events, which in the opinion of the Board, are anticipated in light of the Company’s
activities at the time of granting the obligation to indemnify and is limited to a sum or measurement determined by the Board as reasonable under the circumstances. The indemnification undertaking shall specify such events and sum or
measurement.
|
|
74.2. |
Matters as detailed in Articles 73.2, 73.3 and 73.4.
|
75. |
The Company may indemnify an Office Holder retroactively with respect of the matters as detailed in Article 73, subject to any applicable law.
|
76. |
The Company may exempt an Office Holder in advance for all or any of his liability for damage in consequence of a breach of the duty of care vis-a-vis the Company, to the
fullest extent permitted under the Statutes. However, the Company may not exempt a director in advance from his liability toward the Company due to the breach of his duty of care in the event of a Distribution, as defined in the Statutes.
|
77. |
The above provisions with regard to insurance, exemption and indemnity are not and shall not limit the Company in any way with regard to its entering into an insurance contract
and/or with regard to the grant of indemnity and/or exemption in connection with a person who is not an Office Holder of the Company, including employees, contractors or consultants of the Company, all subject to any applicable law.
|
78. |
Articles 71 through 76 shall apply mutatis mutandis in respect of the grant of insurance, exemption and/or indemnification for persons serving on behalf of the Company as Office
Holders in companies controlled by the Company, or in which the Company has an interest.
|
79. |
An undertaking to insure, exempt and indemnify an Office Holder in the Company as set forth above shall remain in full force and effect even following the termination of such
Office Holder's service with the Company.
|
80. |
Subject to the Statutes, the Annual Meeting shall appoint an Auditor for a period ending at the next Annual Meeting, or for a longer period, but no longer than until the third
Annual Meeting after the meeting at which the Auditor has been appointed. The same Auditor may be reappointed.
|
81. |
So long as the Company is a public company, the Board shall appoint an Internal Auditor pursuant to the recommendation of the Audit Committee.
|
82. |
The organizational superior of the Internal Auditor shall be the Chairman. The Internal Auditor shall submit a proposed annual or periodic work plan to the Audit Committee,
which will approve such plan with changes as it deems fit, at its discretion.
|
83. |
Notwithstanding the provisions of section 327(a) of the Companies Law, the majority required for the approval of a merger by the general meeting or by a class meeting shall be
an ordinary majority of the votes of the shareholders entitled to vote and voting themselves.
|
84. |
Signatory rights on behalf of the Company shall be determined from time to time by the Board.
|
85. |
The Board may decide on a Distribution, subject to the provisions set forth under the Law and these Articles.
|
86. |
The Board will determine the method of payment of any Distribution. The receipt of the person whose name appears on the record date on the Register as the owner of any share, or
in the case of joint holders, of any one of such joint holders, shall serve as confirmation with respect to all the payments made in connection with that share and in respect of which the receipt was received. All dividends unclaimed after
having been declared may be invested or otherwise used by the Directors for the benefit of the Company until claimed, provided however that the Company shall not be required to accept any claim made following the 7th anniversary
of the declaration date, or an earlier date as may be determined by the Board. No unpaid dividend shall bear interest or accrue linkage differentials.
|
87. |
For the purpose of implementing any resolution concerning any Distribution, the Board may settle, as it deems fit, any difficulty that may arise with respect to the
Distribution, including determining the value for the purpose of the said Distribution of certain assets, and deciding that payments in cash shall be made to the Shareholders based on the value so determined, and determining provisions with
respect to fractions of shares or with respect to the non-payment of small sums.
|
88. |
The Company shall be entitled to issue redeemable securities which are, or at the option of the Company may be, redeemed on such terms and in such manner as shall be determined
by the Board. Redeemable securities shall not constitute part of the Company's capital, except as provided in the Law.
|
89. |
The Company may make donations of reasonable amounts of money for purposes which the Board deems to be worthy causes, even if the donations are not made in relation to business
considerations for increasing the Company's profits.
|
90. |
Subject to the Statutes, notice or any other document which the Company shall deliver and which it is entitled or required to give pursuant to the provisions of these Articles
and/or the Statutes shall be delivered by the Company to any person, in any one of the following manners as the Company may choose: in person, by mail, transmission by fax or by electronic form.
|
91. |
Any notice to be given to the Shareholders shall be given, with respect to joint shareholders, to the person whose name appears first in the Register as the holder of the said
share, and any notice so given shall be sufficient notice for all holders of the said share.
|
92. |
Any notice or other document served upon or sent to any Shareholder in accordance with these Articles shall, notwithstanding that he be then deceased or bankrupt, and whether
the Company received notice of his death or bankruptcy or not, be deemed to be duly served or sent in respect of any shares held by him (either alone or jointly with others) until some other person is registered in his stead as the holder or
joint holder of such shares, and such service or sending shall be a sufficient service or sending on or to his heirs, executors, administrators or assigns and all other persons (if any) interested in such share.
|
93. |
The accidental omission to give notice to any Shareholder or the non-receipt of any such notice shall not cancel or annul any action made in reliance on the notice.
|
94. |
(a) Unless the Company consents in writing to the selection of an alternative forum, with respect to any causes of action arising under the U.S. Securities Act of 1933 as
amended, against any person or entity, including such claims brought against the Company, its directors, officers, employees, advisors, attorneys, accountants or underwriters, the federal district courts of the United States of America shall
be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the U.S. Securities Act of 1933, as amended; and (b) unless the Company consents in writing to the selection of an alternative forum, the
competent courts in Tel Aviv, Israel shall be the exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or
other employee of the Company to the Company or the Company’s shareholders, or (iii) any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law. Any person or entity purchasing or otherwise
acquiring or holding any interest in shares of the Company shall be deemed to have notice of and consented to these provisions. This Article 94 shall not apply to causes of action arising under the U.S. Exchange Act of 1934, as amended.
|
|
• |
the equal right to participate in and vote at general meetings of the shareholders, and each share entitles its holder thereof, who is present and participating in the vote,
whether in person or by proxy, to one vote;
|
|
• |
the equal right to participate in any distribution; and
|
|
• |
the equal right to participate in the distribution of assets available for distribution in the event of liquidation of the company.
|
|
• |
alter or add classes of shares, including shares with preference rights, deferred rights, conversion rights or any other special rights or limitations;
|
|
• |
consolidate and/or split all or any of its share capital into shares of larger or smaller par value than the existing shares;
|
|
• |
cancel any registered shares not yet allocated, provided we have made no commitment to allocate such shares; and
|
|
• |
reduce our share capital and any reserved fund for redemption of capital.
|
As of the end of 2024:
|
||
Name of Subsidiary
|
|
Country of Incorporation
|
Nova Measuring Instruments, Inc.
|
|
Delaware, U.S.
|
Nova Measuring Instruments K.K.
|
|
Japan
|
Nova Measuring Instruments Taiwan Ltd.
|
|
Taiwan
|
Nova Measuring Instruments Korea Ltd.
|
|
Korea
|
Nova Measuring Instruments GmbH
|
|
Germany
|
Nova Measuring Instruments (Shanghai) Co., Ltd
|
China
|
|
Nova Measuring Instruments Singapore Pte Ltd
|
Singapore
|
|
Added in January 2025:
|
||
Sentronics Metrology GmbH*
|
Germany
|
NOVA LTD.
INSIDER TRADING COMPLIANCE POLICY
|
Adopted November 6, 2024
|
Contents
|
|
Page
|
||
Introduction and Persons Covered by this Policy |
1
|
||
Explanation of Insider Trading |
2
|
||
Statement of Policies Prohibiting Insider Trading |
5
|
||
Additional Prohibited Transactions |
7
|
||
Rule 10b5-1 Trading Plans |
8
|
||
Execution and Return of Certification of Compliance |
10
|
||
Schedule I Individuals Subject to Pre-Clearance Requirement
|
|
I. |
|
● |
purchases of the Company’s securities from the Company or sales of the Company’s securities to the Company;
|
|
● |
exercises of share options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding
obligations in a manner permitted by the applicable equity award agreement, or vesting of equity-based awards that, in each case, do not involve a market sale of the Company’s securities (the “cashless exercise” of a Company share option through a broker does involve
a market sale of the Company’s securities, and therefore would not qualify under this exception); or
|
|
● |
purchases or sales of the Company’s securities made pursuant to a plan adopted to comply with the Rule 10b5-1 under Securities Exchange Act of 1934, as amended (“Rule 10b5-1”) pursuant to the policies set forth below. For more information about Rule 10b5-1 trading plans, see Section VI below.
|
|
II. |
|
A. |
What Information is Material?
|
|
B. |
What is Nonpublic?
|
|
C. |
Who is an Insider?
|
|
D. |
Trading by Persons Other Than Insiders
|
|
E. |
Penalties for Engaging in Insider Trading
|
|
● |
SEC and ISA administrative sanctions;
|
|
● |
securities industry self-regulatory organization sanctions;
|
|
● |
civil injunctions;
|
|
● |
damage awards to private plaintiffs;
|
|
● |
disgorgement of all profits;
|
|
● |
civil fines for the violator of up to three times the amount of profit gained or loss avoided;
|
|
● |
civil fines for the employer or other controlling person of a violator;
|
|
● |
criminal fines for individual violators; and
|
|
● |
jail sentences.
|
|
F. |
Size of Transaction and Reason for Transaction Do Not Matter
|
|
G. |
Presumption on Use of Material Nonpublic Information by Key Insiders
|
|
III. |
|
A. |
Blackout Periods
|
|
B. |
Pre-Clearance of All Trades by All Officers, Directors and Certain Key Employees
|
|
C. |
Post-Termination Transactions
|
|
D. |
Termination
|
|
IV. |
|
A. |
Short Sales
|
|
B. |
Publicly Traded Options
|
|
C. |
Hedging Transactions
|
|
D. |
Purchases of the Company’s Securities on Margin; Pledging the Company’s Securities to Secure Margin or Other Loans
|
|
E. |
Director and Executive Officer Cashless Exercises
|
|
F. |
Standing Orders
|
|
G. |
Partnership Distributions
|
|
H. |
Gifts
|
|
V. |
|
● |
has been submitted to and pre-approved in writing and in advance by (i) both the Chief Executive Officer and the Chief Financial Officer or (i) either the Chief Executive
Officer or the Chief Financial Officer and one the Company's directors (the "Authorized Officers").
|
|
● |
includes a “Cooling Off Period” as required under Rule 10b5-1, which are as follows as of the date of adoption of this Policy:
|
|
o |
for directors and officers that extends to the later of 90 days after adoption or modification of a Rule 10b5-1 trading plan or two (2) business days after filing the Form 20-F
or Form 6-K with financial results covering the fiscal quarter in which the Rule 10b5-1 trading plan was adopted, up to a maximum of 120 days; and
|
|
o |
for employees and any other persons, other than the Company, that extends 30 days after adoption or modification of a Rule 10b5-1 trading plan;
|
|
● |
for directors and officers, includes a representation in the Rule 10b5-1 trading plan that the directors or officers is (1) not aware of any material nonpublic information about
the Company or its securities; and (2) adopting the Rule 10b5-1 trading plan in good faith and not as part of a plan or scheme to evade Rule 10b-5;
|
|
● |
has been entered into in good faith at a time when the individual was not in possession of material nonpublic information about the Company and not otherwise in a blackout
period, and the person who entered into the Rule 10b5-1 trading plan has acted in good faith with respect to the Rule 10b5-1 trading plan;
|
|
● |
either (1) specifies the amounts, prices, and dates of all transactions under the Rule 10b5-1 trading plan; or (2) provides a written formula, algorithm, or computer program for
determining the amount, price, and date of the transactions, and (3) prohibits the individual from exercising any subsequent influence over the transactions; and
|
|
● |
complies with all other applicable requirements of Rule 10b5-1.
|
|
VI. |
|
(i) |
directors
|
|
(ii) |
officers, Corp vice presidents reporting directly to the Chief Executive Officer and headquarter personnel who have access to sensitive group information on a consolidated basis
outside of the quarterly blackout periods, in each case under (ii) as identified from time to time by the Chief Financial Officer must be pre-cleared by the Compliance Officer and in his absence the Chief Financial Officer.
|
_________________
|
_________________
|
Signature | Date |
_________________
|
_________________
|
Title and Signature |
Date |
|
1. |
I have reviewed this Annual Report of Nova Ltd.
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for,
the periods presented in this report;
|
|
4. |
The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
|
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c) |
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
|
|
d) |
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the
company’s internal control over financial reporting; and
|
|
5. |
The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of company’s board of directors (or persons
performing the equivalent function):
|
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report
financial information; and
|
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.
|
|
1. |
I have reviewed this Annual Report of Nova Ltd.
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for,
the periods presented in this report;
|
|
4. |
The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
|
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c) |
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
|
|
d) |
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the
company’s internal control over financial reporting; and
|
|
5. |
The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of company’s board of directors (or persons
performing the equivalent function):
|
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report
financial information; and
|
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.
|
|
1. |
This Annual Report on Form 20-F of Nova Ltd. (the “Company”) for the period ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ Gabriel Waisman
Gabriel Waisman
President and Chief Executive Officer |
|
1. |
This Annual Report on Form 20-F of Nova Ltd. (the “Company”) for the period ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, as amended; and
|
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ Guy Kizner
Guy Kizner
Chief Financial Officer |